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REJUVENATION OF THE EPIGENETIC LANDSCAPE OF THE AGED BRAIN
THROUGH MANIPULATION OF CIRCULATING FACTORS

Edward Charles Koellhoffer, B.S.

Advisory Professor: Louise Deborah McCullough, M.D., Ph.D.

The aging population of the United States is expanding at an alarming rate. The
Center for Disease Control and Prevention estimates that the population of those age
65 years and older will reach over 50 million by 2020 and will double to 100 million by
2060. This will not only put a massive strain on national healthcare resources, but will
also increase the number of those who are not able to live and function independently.
It is becoming increasingly vital to understand how the brain changes with age and
mechanisms to possibly protect and rejuvenate the aged brain to a younger, healthier
phenotype to promote healthy aging.
In this work, we found that there is an increase in the number and amount of
pro-inflammatory cytokines in the brain with age, demonstrating that the brain becomes
progressively pro-inflammatory with age. Notably, we observed an increase in IFNγ
and GM-CSF which are two cytokines implicated in the detrimental priming phenotype
of the aged brain. Additionally, we found that the aged brain becomes epigenetically
dysregulated, with an increase in Ezh2 function and simultaneous loss of the opposing
function of Jmjd3, thereby leading to a respective increase in H3K27me3 and decrease
in H3K27me1 in the brain with age. Furthermore, when we examined the role of Ezh2
in primary microglia cultures in vitro, we found that inhibition of Ezh2 could
vii

simultaneously abrogate pro-inflammatory polarization and enhance anti-inflammatory
polarization. Together, this data suggests that increasing function of Ezh2 may directly
contribute to the pro-inflammatory phenotype of the brain with age.
We also found that culturing primary microglia with plasma from healthy aged
mice resulted in up-regulation of pro-inflammatory cytokines Il1b and Il6 in vitro,
suggesting that circulating peripheral factors may directly influence the transition of the
brain to a pro-inflammatory phenotype with age. We tested if the age-associated
epigenetic dysregulation and pro-inflammatory phenotype could be reversed by utilizing
the surgical model of heterochronic parabiosis. In this model, a young and aged animal
are surgically attached so that the two come to share a common blood supply. Using
young-young and aged-aged isochronic surgical controls, we found that young blood
rejuvenates the levels of H3K27me3 to those of a younger animal. Additionally, when
we induced a neuroinflammatory response in the heterochronic and aged isochronic
parabionts, we found that the neuroinflammatory response of aged heterochronic
animals was rejuvenated and reduced compared to aged isochronic controls.
This work is the first to investigate the role of epigenetic dysregulation of Ezh2
and Jmjd3 in the brain with age. Additionally, this is the first work to examine the ability
of the circulating peripheral immune system to rejuvenate the epigenetic landscape of
the aged brain and functional response to a pro-inflammatory stimulus. Future
identification of the specific circulating peripheral factor(s) responsible for brain aging
and rejuvenation may allow for therapeutic intervention to promote healthy brain aging
in older individuals.
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Chapter 1:
Introduction

This chapter is based upon:
Koellhoffer, Edward C., Louise D. McCullough, and Rodney M. Ritzel. "Old Maids:
Aging and Its Impact on Microglia Function." International journal of molecular sciences
18.4 (2017): 769.
Reprinted with permission.
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Introduction
By 2050 the global life expectancy is expected to increase by nearly eight years.
However, the quality of life of the estimated ~17% of world’s population soon to be over
65 years will not necessarily be any better due to the increasing burden of age-related
diseases such as stroke and other neurodegenerative diseases. The rate of dementia
will increase from 9.4% to 23.5% by the mid-century, and the number of people living
with Alzheimer’s disease in the U.S. is expected to grow by nearly 10 million (1). By
2030, nearly 4% of the U.S. population is projected to have had a stroke, straining our
already limited resources and health infrastructure (2). Our scientific understanding of
normal aging processes is incomplete and the mechanisms leading to age-related
disability with the advent of age-mitigating/rejuvenation therapies needs further
exploration.
The effects of aging on the central nervous system (CNS) are widespread, as
are systemic changes in peripheral tissues. The importance of communication
between the CNS and the periphery is increasingly recognized, and may be mediated
by systemic factors, the autonomic nervous system, commensal bacteria (i.e., the
microbiome) and/or the neuro-immune axis. Age-related changes in CNS homeostasis
are not solely intrinsic in nature, but are mediated through bidirectional communication
between the CNS and the systemic environment (Figure 1.1). Differences in neuronal
function have been observed in the CNS with age, but it is becoming increasingly
apparent that it is possible to slow, or even reverse, aging by restoring “youthful”
peripheral tissue compartments (3, 4). This includes the bone marrow niche that gives
rise to the body’s immune system, which can have a beneficial positive feedback effect
on distant areas including the CNS.
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Figure 1.1. The impact of aging on microglia function and its systemic regulation.
Young microglia (in pink) gradually transition from a ramified morphological state to a
deramified, spheroid formation with abnormal processes with chronological age.
Several cytoplasmic features are hallmarks of microglial senescence including
increased granule formation, autofluorescent pigments such as lipofuscin, and process
fragmentation. Age-related neuronal loss (in red) reduces the overall level of
immunoinhibitory molecules (e.g., CD200, CX3CL1) required to maintain microglia in a
quiescent state. Basal increases in inflammatory signaling are associated with
enhanced ROS production which results in the generation of free radicals, lipid
peroxidation, and DNA damage. This positive feedback loop is further compounded by
defects in lysosomal digestion and autophagy, resulting in the potentially toxic buildup
of indigestible material. Concurrent reductions in process motility and phagocytic
activity lead to decreased immune surveillance and debris clearance, resulting in
plaque formation (beige). In turn, microglia activation triggers astrocyte activation (in
orange) and promotes the recruitment of T cells (in blue) into the aging brain. These
pathological features of microglial aging are highly influenced by the systemic
3

environment. Diminished levels of circulating anti-aging factors in conjunction with
increased concentrations of pro-aging factors are critical drivers of microglial
senescence. For example, diminished estrogen levels in older (menopausal) females
are associated with elevated expression of macrophage-associated genes in the brain.
Therapeutic interventions intended to increase anti-aging factors and decrease proaging factors appear to be able to halt or delay microglia aging, enhance neurogenesis,
and improve cognitive function.

4

Inflammation is viewed as a central driver of aging and/or age-related
dysfunction. The term ‘inflamm-aging’ was coined to describe the ever subtle but
gradual increase in inflammatory signaling with age (5, 6). Although inflamm-aging is
primarily macrophage-driven, the accrued effects of this are widespread, affecting
nearly all cells at either the intrinsic or extrinsic level—to an extent that fundamentally
alters normal physiological behavior—as evidenced by the overall age-related decline
in normal function. Characteristics of the aged brain such as gray matter loss and
cortical thinning, shrinkage in hippocampal volume, deficits in learning and memory,
and decreased remyelination (see Figure 1.2) are all processes that have been
empirically proven to involve inflammation, the severity of which likely depends on the
level of degeneration and how it is modulated.

5

Figure 1.2. A: MRI of a normal 32-year-old woman. There is no evidence of atrophy or
white matter disease. B: MRI of a 78-year-old woman with mild cognitive impairment.
There is considerable frontal temporal atrophy as seen by an enlarged Sylvian fissure
(asterisks) and white matter disease (white arrow).
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No cell is protected from the detrimental effects of aging, and this includes the
primary immune cell of the CNS, the resident tissue macrophages known as microglia.
These cells represent 5-15% of all brain cells, and are considered to be the
housemaids of the CNS, providing nourishment and support to neighboring neurons,
clearing debris, and being the first responders to foreign stimuli (7). Like their neuronal
counterparts, microglia are believed to be post-mitotic and long-lived, with minimal, if
any, turnover. Although recent depletion studies imply the existence of latent microglia
progenitors, it is not clear what role this proposed population of cells may have in
replenishing microglia populations under normal homeostatic conditions across the
lifespan (8). Thus, these cells may still be viewed as especially vulnerable to the
cumulative effects of aging, and thus, poised to negatively impact the neurovascular
niche as a result of a compromised ability to perform essential ‘house-keeping’
functions. While the role of aging on circulating macrophages and other lymphoidassociated myeloid cells has received significant attention in recent years, our
understanding of the age-related changes in the function of CNS-resident microglia is
less clear. This review highlights current findings and concepts on the effects of aging
on microglia and stresses their potential contribution to inflamm-aging and age-related
stress.

Age-related changes in microglia phenotype
Aged microglia exhibit increased soma volume, a retraction in processes, and a
loss in uniform tissue distribution (9). Moreover, microglial process speed is
significantly slower with age in healthy and injured animals, resulting in less active
tissue sampling and impaired synaptic contact (10). These age-related abnormalities in
7

cytoplasmic structure, deramification, and process fragmentation were collectively
termed ‘microglial dystrophy’, and are more indicative of a senescent rather than
classical activation phenotype (11, 12). The newly coined ‘dark’ microglia phenotype
defined by condensed electron-dense cytoplasm and nucleoplasm, nuclear chromatin
remodeling, and high levels of synaptic stripping activity and oxidative stress applies
not only to microglia populations associated with pathological states such as chronic
stress and Alzheimer’s disease, but to the microglia that are observed in normal aging
(13). While these alterations at the ultrastructural level are only now beginning to be
described, it has been well known that aged microglia are highly granular and atypically
dark in appearance in immunohistological preparations. Defects in lysosomal digestion
can result in the progressive accumulation of indigestible material largely composed of
lipofuscin and other autofluorescent pigments (14, 15). Researchers studying protein
expression in aged microglia using immunofluorescence or flow cytometry techniques
are likely familiar with the high degree of autofluorescence in these cells. Age-related
microglia-associated autofluorescence is often viewed as a technical nuisance as it is
difficult to differentiate changes in the normal CNS or those due to severe injury. The
accumulation of lipofuscin and other non-degradable autofluorescent byproducts is
believed to be due to impairment in disposal mechanisms and has also been implicated
in several neurodegenerative diseases including Alzheimer’s disease (16, 17).

Strategies to investigate functional characteristics of microglia
Not all aged microglia exhibit an “aged” phenotype, and it is unclear whether
autofluorescence is confined to dystrophic (i.e., dysfunctional) microglia populations in
select regions or if it is a more widespread phenomena, as it is currently difficult to
8

isolate these cells and evaluate their function relative to their non-autofluorescent
counterparts. Using flow cytometry, our lab has recently identified a significant
population of side scatter-high microglia in the aged brain that exhibit a surprising level
of both granular content and autofluorescence background (18). These cells display
functional abnormalities when compared to young microglia and more importantly, to
side scatter-low microglia that co-exist alongside them in the aged CNS (see Figure
1.3). These functional abnormalities include higher production of reactive oxygen
species (ROS) and pro-inflammatory cytokines, increased mitochondrial content, and
poor phagocytic ability—all features of a senescent or dystrophic macrophage
phenotype. However, if the proper precautions are not taken, aged microglia can
appear to stain positive for nearly any antibody or fluorescent label. Because of this
artifact, the high level of background exhibited by aged microglia requires the use of
fluorescence-minus one (FMO) or isotype controls specifically using aged brains and
subsequently gating on aged microglia to determine the true background level—which
in studies from our laboratory appear to be greater than that of any other immune cell in
the body. Other methods of masking or quenching autofluorescence such as Sudan
Black B have been developed and are often employed during histological preparations
(19). Given the clinical ramifications of lipofuscin accumulation in both neurons and
glia, future efforts to develop brain-imaging techniques which can exploit the naturally
occurring level of autofluorescence (i.e., lipofuscin-like material) in the CNS may prove
highly useful in predicting or diagnosing neurological disease states in humans.
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Figure 1.3. Age-related microglial dystrophy. Confocal microscopy images of DAPIcounterstained (blue) Iba1-positive cortical microglia (pink) highlight the enlarged soma
and abnormal, twisted cytoplasmic processes of aged microglia (A). Flow cytometry
int

+

-

preparation of CD45 CD11b Ly6C microglia demonstrate a significant increase in
cellular granularity and size with age (B). A population of side scatter-high aged
microglia exhibits high levels of autofluorescence (FITC channel) compared to their
younger counterparts and is indicative of lysosomal dysfunction (C).
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Despite several reports demonstrating prolonged maintenance of aged microglia
in vitro (20, 21), for many, the long-term culture of microglia isolated from aged brains
can be technically challenging if not impossible. These methods are invaluable to the
study of intrinsic age-related changes in microglia function. One alternative approach
is the immediate ex vivo functional assessment of freshly harvested cells. Although
some activation is induced during the mechanical/enzymatic digestion procedure via
crude extraction from their native microenvironment (e.g., loss of contact-inhibitory
signaling), this confounder is seen by many to be unavoidable and perhaps necessary
in order to understand their functional activity. Ex vivo functional testing is
advantageous for aging studies because it allows the investigator to probe for intrinsic
microglia activity in a very acute time window (within hours), obtaining as close to their
presumed in vivo functional identity as possible with minimal artifact introduced by
standard cell culture systems. Indeed, a recent report suggests that neonatal microglia
undergo dramatic ‘age-like’ changes in as short of time from 2 days in vitro to 16 days
in vitro (22). Nonetheless, in vitro approaches are currently indispensable and the
advent of more efficient long-term culture methods will hopefully allow researchers to
address many important questions that ex vivo testing is not well suited for.
Another issue regarding the activation status of microglia is the suitability of the
existing nomenclature and its application to age-related microglial phenotypes. The
long-held M1/M2 convention for describing macrophage polarization may be more
applicable to in vitro systems than for far more complex in vivo environments, as mixed
phenotypes are commonly seen (23). The M1/M2 in vitro paradigm, originally premised
on infection studies, attempts to explain the predisposition for peripheral macrophages
to respond as either ‘inflammatory’ (M1) or ‘reparative’ (M2) subsets depending on their
exposure to the cytokine byproducts of polarized T cell subsets (Th1: IFNγ or Th2: IL11

4). Subsequent transcriptomic profiling has demonstrated significant differences
between bone marrow-derived monocyte populations and CNS-resident microglia,
which may be due in part to the age (high vs. low turnover) and environment
(circulation vs. brain) of the cells being profiled, and any interactions between the two.
An expert analysis of this controversy was recently discussed by Ransohoff (24).
Among the many salient points expressed was the lack of predicted transcriptional
organization found between polarization states induced in several disease models as
demonstrated by ex vivo expression profiling of microglia, indicating that microglial
reactivity is multifactorial and injury-specific, and thus, unlikely even to fall along a
linear continuum. The application of M1/M2 markers for the in vivo description of
microglia activation states is then seemingly inadequate in defining the injury-resolving
capacity of these cells and their associated functions. Thus, it would seem that
attempting to classify the pro-inflammatory phenotype of aged microglia as M1 may be
too simplistic in that it ignores the adaptive requirement of these cells to respond to the
demands of a changing microenvironment over the lifespan (25). In recent years, the
senescence-associated secretory phenotype, or SASP, has been utilized to more
accurately describe aged senescent cells, however these criteria may vary depending
on cell type, especially as not all aged cells are senescent per se (26, 27). Aged
microglia are likely to exhibit many of the same phenotypic features as other aged postmitotic tissue-resident macrophages. Although SASP criteria have yet to be
established specifically for microglia, emerging studies suggest a framework for one will
emerge in the next few years.

Reactive oxygen species-mediated damage in the aging brain:
12

One of the most profound changes that occurs with aging is the gradual increase
in reactive oxygen species (ROS) generation. Indeed, glial cell activation and elevated
oxidative stress burden are hallmarks of CNS aging and manifest during the course of
many if not all neurodegenerative diseases (Figure 1.4). As the predominant myeloid
cell in the nervous system, microglia are the main source of oxidation products and
inflammatory mediators during aging. Elevated microglia ROS production (e.g.,
superoxide anion, hydroxyl radical, and lipid hydroperoxides) can impose a hazard to
nearby neurons either through direct release (i.e., neurotoxicity) or via second
messenger signaling pathways such as PKC, MAPK, and NF-κB activation which serve
to intensify the pro-inflammatory response (28). The importance of ROS to age-related
neuropathology is evidenced in its key capacity to mediate the detrimental effects of
amyloid beta (Aβ) and lipopolysaccharide (LPS)-induced CNS injury (29, 30). LPS
induces the generation of ROS from the actively respiring mitochondria as well as
NADPH oxidase (NOX). Superoxide production via NOX has been shown to be the
main contributor of ROS in several age-related neurodegenerative diseases and is
linked to the classical activation of microglia (31). Ansari and Scheff reported an
inverse correlation between NOX activity and cognitive impairment, in which higher
NOX activity was associated with worse cognitive performance in individuals of all
stages of Alzheimer’s disease (32). Indeed, NOX2-deficiency has been shown to
reduce oxidative stress, leading to improved cerebrovascular function and behavior in a
mouse model of Alzheimer’s disease. For example, chronic treatment of apocynin, a
NOX inhibitor, reduced plaque size and microglia number in hAPP(751)(SL) mice (33).
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Figure 1.4. Imbalance between oxidative stress and antioxidant defenses in
the aging brain. Oxidative stress arises when there is an excess of free radicals
over antioxidant defenses. This imbalance leads to an inability to detoxify the
reactive intermediates and results in oxidative damage of genes and proteins.
Oxidative stress is a consequence of the aging process and is involved in many
diseases such as Alzheimer’s disease, stroke, and atherosclerosis. Stressactivated pathways impact gene expression and alter the normal function of
cells, often resulting in respiratory chain dysfunction, altered proteostasis,
telomere shortening, apoptosis, and cellular senescence.
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One of the hallmarks of Alzheimer’s disease is cerebral amyloid angiopathy
(CAA), which is characterized by the deposition of Aβ within the walls of cerebral
arterioles. Treatment with apocynin and tempol, a non-specific ROS scavenger,
attenuated ROS production and improved cerebrovascular function in aged Tg2576
mice (34). Treated mice exhibited a reduction in CAA formation and CAA-related
microhemorrhages, indicating that NADPH oxidase-derived ROS are a key contributor
to CAA formation and associated vascular dysfunction. Together these findings
suggest that the age-related increase in microglial ROS production has widespread
effects on the neurovascular niche and may be a key accelerant of neurodegenerative
disease and cognitive impairment.
Microglia are thought to be the main mediator of ROS-induced neuronal injury
and several studies have demonstrated that NADPH oxidase-deficient primary
microglia exhibit blunted levels of intracellular ROS, extracellular superoxide, TNF
expression, and neurotoxicity following LPS stimulation in vitro (30, 35). NOX may
even play a critical role in the development of chronic inflammation as previous work
has shown that NOX2-deficient mice exhibit less dopaminergic neurodegeneration in
the substantia nigra 10 months after a single systemic LPS injection compared to
NOX2+/+ controls (35). It is possible that loss of NOX function attenuates ROS
production by the infiltrating neutrophils and monocyte-derivatives in the hours and
days following injury. Interestingly though, microglia from NOX2-deficient mice fail to
show any increase in activation morphology as early as 1 hour following injection,
implying that it is the early wave of ROS production that determines the severity of
disease course.
As noted above, both NOX and ROS levels increase in the CNS with normal
aging and following injury. ROS production and lipid peroxidation is significantly
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elevated in older mice after contusion spinal cord injury compared to young controls
(36). NOX2 expression was greater in ROS-producing microglia/macrophages in the
lesion site of older mice. Interestingly, aging is also associated with a loss of free
radical scavenging mechanisms. Antioxidant defenses have been shown to be
attenuated in aged microglia, as evidenced by reduced cellular levels of glutathione
and dysregulation of heat shock proteins such as heme-oxygenase 1 (37, 38). The
potential for antioxidant therapy to improve microglia aging and, in turn, brain aging has
recently been reviewed (39). As of yet it is still unclear whether worsening injury with
age is primarily a result of exacerbated or chronic microglial production of ROS or if
aging neurons are just more susceptible to ROS-mediated damage.

Neuronal-glial interactions and immunoinhibitory signaling in the aging brain:
In addition to intrinsic age-related stress, microglia are highly responsive to
environmental stimuli throughout the lifespan, including extrinsic immunological
stressors. As guardians and primary caretakers of the more vulnerable neuronal
populations, the manner in which microglia respond to these stressors is critical for
normal neuronal function. Activated microglia exhibit augmented production of
inflammatory cytokines, ROS, and metabolic byproducts known to be neurotoxic.
Thus, given their complex array of activation-sensing receptors and complementary
inhibitory receptors, microglia are tightly regulated to deliver calibrated responses to
any given stimulus across space (gradient effects) and time (from pathogenesis to
resolution phase). To avoid over-activation and any resultant bystander damage, the
requirement for microglial inhibitory receptors is essential to not only prevent the
generation of unwanted inflammation, but to also ramp down injury-driven inflammatory
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responses once they are largely resolved. However, with age, the ability of these
inhibitory receptors to maintain microglial quiescence is impaired in part due to
reductions in the expression of their cognate ligands.

CD200/CD200R1:
The CD200-CD200R1 immunoinhibitory signaling axis in the CNS is comprised
of gray matter neurons that ubiquitously express CD200 both stably on their surface
and in secreted form, and microglia/macrophages which express the receptor for this
ligand, CD200R1. Microglia/macrophage immune responsiveness is believed to be
constitutively down-regulated under normal conditions via direct interactions with
neighboring neurons, leading to microglial quiescence. Interestingly, young adult mice
that are deficient in CD200, exhibit many features seen in normal aging mice such as
basal increases in microglia activation, T cell infiltration, blood-brain barrier
permeability, impaired long-term potentiation (LTP), and exacerbated responses to
injury and disease (18, 40–42) implying that CD200 levels may naturally diminish with
normal aging (43). Concomitant increases in transcriptional expression of proinflammatory genes and decreases in anti-inflammatory genes such as Cd200 have
since been demonstrated in the substantia nigra and hippocampus of older animals
(44, 45) leading one to speculate that the lack of microglia inhibition leads to greater
inflammation which is detrimental to learning and memory.
CD200 expression is decreased in the brain of Alzheimer’s patients and Aβchallenged mice (46). Subsequent in vivo studies demonstrated that intrahippocampal
administration of CD200 fusion protein decreased microglial activation and decreased
LTP deficits in both aged and LPS-treated rats (47). Activation of CD200R1 by CD200
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fusion protein inhibited Aβ-induced increases in IL-1β, TNF, CD40, and CD68 (48).
Moreover, Aβ-induced deficits in LTP were attenuated by CD200 fusion protein in
hippocampal slice culture. Consistent with these findings, the delivery of an adenoassociated virus expressing CD200 into the hippocampus of APP mice for a period of 6
months restored neurogenesis and reduced diffuse plaques in 12-month-old mice (49).
Additionally, the authors found that in vitro stimulation of microglial CD200R1 promoted
neuronal growth and despite being anti-inflammatory, resulted in greater Aβ
internalization. This is in contrast to a new report that has shown microglia from
CD200-deficient mice exhibit increased lysosomal and phagocytic activity in response
to Aβ challenge (50). This effect was mediated in part by mTOR inhibition and implies
that CD200 normally functions to suppress immune functions such as phagocytosis.
Alternatively, it is possible that the chronic loss of functional CD200 in these knockout
models over the lifespan could prime microglia to respond in a manner that is not
consistent or comparable to microglia from otherwise normal, healthy wildtype mice.
As is the delicate balance of any regulatory system, the potential to increase inhibitory
signaling may be offset the adaptive requirement for activation (e.g., injurysensing/stimulus recognition, migration to injury sites, debris clearance and phenotype
switching). Thus, it is not yet clear whether pro-inflammatory-induced activation of
microglia is required to drive phagocytic activity and a return to homeostasis or if
chronic inflammation impedes normal function as appears to be the case in the aging
brain.

CX3CL1/CX3CR1:
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The chemokine fractalkine (CX3CL1) which is expressed on neurons in
membrane-bound form or secreted by neurons functions similarly to CD200,
suppressing activation by binding to its receptor, CX3CR1, expressed on microglia.
This interaction is important for downregulating microglial activation and maintaining
CNS homeostasis (51, 52). Fractalkine signaling is similarly impaired with normal
aging, following LPS challenge, and in APP(swe) transgenic mice, as expression levels
for both the ligand and the receptors have been shown to be significantly decreased
and inversely associated with inflammatory activity (52–55). The age-related loss of
fractalkine ligand in the rodent hippocampus is associated with decreased
neurogenesis; however the survival and proliferation of neuronal progenitor cells was
restored by exogenous fractalkine, an effect that was not seen in young animals
suggesting that this was an age-dependent mechanism (56). Protracted
downregulation of the fractalkine signaling pathway is associated with delayed recovery
from sickness behavior, elevated IL-1β levels, and decreased TGFβ production in the
aged brain (57). However predictable the outcome of fractalkine receptor activation on
microglia might seem, several reports highlight the complex nature of this immune
inhibitory signaling. For example, intrahippocampal injection of Aβ fibrils was found to
upregulate CX3CR1 expression on activated microglia and increase synaptic
dysfunction and cognitive impairment (58). It is not surprising that CX3CR1 expression
was enhanced by Aβ stimulation, as many immune inhibitory receptors are known to
upregulated in classically activated microglia/macrophages in an effort to counteract
the pro-inflammatory state. Both CX3CL1- and CX3CR1-deficiency have been shown
to reduce Aβ deposition in APPPS1 mice, and an increase in microglial p38MAPK
activation and cytokine production (59, 60). In other studies, CX3CR1-deficiency
resulted in worsened neuronal and memory deficits in hAPP mice independent of
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plaque load (61). Despite the reduction in Aβ plaque deposition, CX3CR1-deficient
mice exhibited exacerbated Tau pathology, an effect that was subsequently shown to
be suppressed by fractalkine overexpression (62). Together, these findings suggest
that a delicate balance of activating and immunoinhibitory signaling is likely required to
perform the full spectrum of function required to maintain homeostasis in the aged CNS
environment.

Phagocytosis in the aging brain:
Debris clearance is an essential role of microglia. Normal aging has significant
effects on endocytic pathways, including the phagocytic uptake of debris.
Transcriptional analysis of acutely isolated microglia from APPswe/PS1dE9
Alzheimer’s disease (AD) mice reveal diminished expression of genes associated with
phagocytosis (63). At the functional level, young microglia (1 month old mice)
internalize ~50% more Aβ42 than aged microglia (15 month old mice), demonstrating
an age-related decrease in phagocytic behavior beginning at birth (< 8 days old mice)
(37). Data from our laboratory has shown age-related deficits in the phagocytosis of
physiological (Aβ) and non-physiological (latex beads) cargo not only at baseline, but
also following ex vivo stimulation with PMA/ionomycin (18). While aging negatively
affects the ability of microglia to phagocytose Aβ, it does not appear to limit their ability
to adhere to amyloid plaques or in vitro fibrillized Aβ (64). Moreover, aging did not
affect the functional uptake of bacterial bioparticles, and others have reported that aged
microglia exhibit greater uptake of quantum dots (65), implying that aging may
differentially affect phagocytic pathways at various stages (adherence, internalization,
digestion, etc.) or with different substrates. In an interesting study by Hendrick in 2014,
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the authors showed that while aging enhanced microglial capacity for myelin
phagocytosis, it simultaneously reduced myelin’s susceptibility for uptake, suggesting
that age-related phagocytic impairment may be mediated both by intrinsic and extrinsic
factors, depending on the nature of the substrate (66).
Inhibitory ‘don’t eat me’ signals that prevent host attack such as CD47 have also
been shown to prevent microglia phagocytosis of healthy cells via activation of the
immune inhibitory receptor signal regulatory protein-α (67), although it is unclear what
role if any molecules like these have in aging. The ability of a given phagocytic
substrate to induce microglia activation either through toxicity or via receptor-mediated
signaling may in turn alter the phagocytic potential of that cell (68). For example, aging
decreases microglia and monocyte uptake of α-synuclein oligomers and is associated
with increased TNF secretion (69). The age-related increase in microglia cytokine
production, specifically TNF family members, has been demonstrated numerous times
and is a hallmark of CNS aging. However, the nature of the relationship between
increased TNF production and microglia phagocytosis is one that warrants greater
examination, as several studies support an inverse relationship with age. For example,
TGFβ-induced phagocytosis is abolished in aged microglia compared to their younger
counterparts, indicating that receptor-signaling pathways are significantly altered with
age and may underlie endocytic impairment (70). The interactions between cytokine
signaling and phagocytosis have proven to be highly complex and provocative, as
newly emerging data suggests that microglial phagocytosis and plaque clearance may
be suppressed as result of an overproduction of anti-inflammatory molecules such as
IL-10 and arginase-1, rather than mediated by pro-inflammatory dysfunction (71–73).
While our understanding of age-related changes in microglial phagocytosis and
changes in the expression of scavenger receptors (i.e., CD36) is infancy, the
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development of novel drugs that are capable of directly modulating phagocytic activity
and reducing plaque load is becoming a realistic goal.

Microglial depletion and implications to aging:
Just as conditional genetic targeting approaches have advanced our
understanding of the molecular mechanisms underlying microglial activation, recent
pharmacological and genetic microglia depletion studies have aided our understanding
of the net effect of these cells on aging and age-related cognitive decline. These
innovative strategies take advantage of several known aspects of microglial identity
and requirements for survival. For instance, colony-stimulating factor 1 receptor
(CSF1R) is essential for the growth and survival of microglia and other monocytederived cells. CSF1R blockade with PLX5622 eliminates microglia for sustained
periods of time, allowing for the long-term investigation of microglia in
neurodegenerative disease models (74). PLX5622-induced depletion of microglia
prevented their association with plaques, but did not alter amyloid-β levels or plaque
load. Importantly, this strategy was able to reduce overall neuroinflammation and
attenuated contextual memory deficits in 10-month-old 3xTg-AD mice, without having
any overt effect on behavior or cognition in normal adult wild type mice. It is unclear
whether microglial depletion in wild-type aged animals has the potential to have a
positive cognitive benefit. Administration of the CSF1R inhibitor PLX3397 improved
functional recovery and spared neuronal loss in part by reducing chronic inflammation
in 5-8 month old mice following a hippocampal lesion induced by diphtheria toxin
exposure (75). This strategy, similar to what was seen with other CSF1R treatments,
was accompanied by an increase in dendritic spine density, suggesting these cells
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have critical roles in sculpting synapses even after development. PLX5622 also
prevented whole-brain irradiation-induced memory deficits in young mice in part by
limiting microglia proliferation and monocyte infiltration (76, 77). These studies have
enhanced our knowledge of both the homeostatic role of microglia and their functional
contribution to disease pathology. Insights into the global effects of dystrophic
microglia in normal aging using similar depletion approaches could prove extremely
useful to our understanding of the contribution of microglial senescence to age-related
cognitive decline.

Systemic regulation of microglia aging:
Although it is true that the CNS is largely protected from the systemic
environment, it is not impermeable to it. Indeed, systemic administration of LPS has
been found to induce microglia activation, neurodegeneration, and sickness behavior
(78). Thus, it is evident that the brain is influenced by changes in peripheral
homeostasis. Although the brain is protected by the blood-brain barrier, there are
several conduits through which systemic messages reach the CNS, including the
vascular and lymphatic networks, and via the choroid plexus and cerebrospinal fluid.
These anatomical interfaces, which likely convey vital information under healthy
conditions, may also predispose the brain to the detrimental effects of systemic aging.
Work by Baruch et al demonstrated that aging induces a type I interferon (IFN)dependent gene expression profile in the choroid plexus (79). Interestingly, blocking
IFN-I signaling in the aged brain down-regulated IFN-I-dependent gene expression in
the choroid plexus, restored hippocampal neurogenesis, improved cognitive function,
and partially reversed age-related glial activation. These findings suggest that age23

related microglial dystrophy (i.e., senescence) can be reversed by external modulation.
Other blood-brain borders may similarly affect microglia function with age in a locationdependent fashion. Regional heterogeneity in microglia function and differences in
immune vigilance are likely to become exacerbated with age as neurovascular function
and blood vessel integrity has been reported to be selectively compromised in the
hippocampus and frontoparietal cortex (80–82). Pioneering studies using
heterochronic parabionts and plasmapheresis support a strong link between the
systemic environment and brain aging. Systemic immune factors such as CCL11 and
β2-microglobulin are elevated in an age-dependent manner in the plasma and
hippocampus, and impair neurogenesis and cognitive function (83, 84). Systemic
exposure to either molecule induced similar deficits in learning and memory that were
reversed by antibody blockade. These studies convincingly demonstrate the important
link between the brain and the periphery. How this bi-directional communication occurs
is a very active and novel area of research, as drug and antibody delivery is much
easier in the periphery due to poor blood-brain penetrance. Manipulating systemic
factors to influence brain inflammation in very appealing for therapeutic development.
One example of bidirectional communication is illustrated by studies examining
the gut-brain axis. Recent work has demonstrated a modulatory effect of gut
microbiota on microglia function (85). Germ-free mice exhibited altered microglia
morphology and impaired responses to LPS stimulation and viral infection (86). Similar
changes in microglial phenotype were seen following partial ablation of microbiota by
oral antibiotics that were normalized following recolonization with microbiota from
specific-pathogen free mice. Mice deficient in the short-chain fatty acid (SCFA)
receptor FFAR2 had similar deficits in microglia function as did germ-free mice,
suggesting that microbiota-derived SCFA exert systemic control over microglial
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development and homeostasis. While compositional shifts in microbiome complexity
have been shown to occur with age, the significance of these changes and their effect
on microglial behavior remains to be seen. Nevertheless, these studies highlight a
critical role for the systemic environment in regulating microglia activity and even
suggest that brain aging may be mitigated by healthy lifestyle choices and dietary
manipulations (87–90).

The role of aging on the microglial response to brain injury and disease
As reviewed above, microglia undergo drastic phenotypic changes with age.
These molecular and cellular changes are many, and their summation leads to a
dysregulated microglia phenotype. Additionally, these phenotypic changes may be
influenced by the changes in the periphery, including microbiome changes (86), ageassociated perfusion deficits within the brain itself (91), and even diet (92). Aging is, no
doubt, a complex process and takes its toll on microglia phenotype and function in
homeostasis. What is also crucial to consider are the effects of aged microglia in the
context of injury and disease in both humans and the animal models we use to study
them. Here we now review the effects and noteworthy issues raised by these ageassociated changes in microglia function in a number of neurological injuries and
diseases.

Aging exacerbates lipopolysaccharide-induced pro-inflammatory microglial response:
As animals and humans age, there are notable changes in cognition and
reaction times even in healthy subjects, and may be an unavoidable consequence of
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aging (93). However, studies in animals have shown that age-related cognitive decline
is correlated with higher levels of pro-inflammatory cytokines produced by microglia
and that the aging brain is sensitized to immune challenges (94). Aged individuals are
more susceptible to delirium when ill with a peripheral infection, stress, or following
surgery, recently reviewed elsewhere (95–98). This is also observed in animal models
(see Table 1.1). These symptoms are associated with activation of the peripheral
innate immune system, and in turn leads to an exacerbated inflammatory responses in
the aged brain (99–101).
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Stressor
Peripheral
infection

Central
innate
immune
activation
Surgery

Stress

Study

(99)

Animals
BALB/c
mice

Age(s)
Young 3-6m
Aged 20-24m

Sex
Male

Model
LPS i.p.
injection

(102)

F344XBN
rats

Young 3m
Aged 24m

Male

Live E. coli i.p.
injection

(103)

BALB/c
mice

Young 3-4m
Aged 20-22m

Male

LPS i.c.v.
injection

(104)

BALB/c
mice

Young 4-6m
Aged 23-25m

Male

(105)

C57Bl6/J
mice

4m

Female

(106)

C57Bl6/J
mice
BALB/c
mice

2m-8m

Female

Young 3-5m
Aged 22-24m

Male

1.5 cm
abdominal
incision and
gentle
manipulation
of internal
organs for 1
min
0.5cm
abdominal
incision
Simple
laparotomy
30min
restraint
stress daily for
4d

(107)

Notable findings
• Exaggerated ↑ IL-1β, IL-6, lipid peroxidation
in aged brain
• ↓ social behavior, food intake, weight loss in
aged
• At baseline: ↑ hippocampal HMGB1 protein,
mRNA in aged; ↑ HMGB1 protein in CSF of
aged
• Following i.p. E. coli injection: Prolonged ↑
expression of IL-1β, IL-18, TNF in aged;
prolonged sucrose anhedonia (depression)
and ↓ juvenile social exploration in aged
• Inhibition of HMGB1: abrogated primed
phenotype of aged brain to peripheral E. coli
injection, restoring behavior to that of young
animals
• Prolonged ↓ locomotor activity, social
behavior, and food intake in aged
• ↑ cerebellar and hippocampal IL-1β, IL-6,
and TNF expression in aged
• Anesthetic and analgesics: no effect on
hippocampal IL-1β, IL-6 and TNF mRNA
expression
• Surgery: ↑ IL-1β expression in aged
hippocampus; locomotor activity unchanged
in in young or aged mice
• Surgery ↑ anxiety, ↓ special memory
• Surgery ↑ total alpha-synuclein and
S100beta in the cortex, ↓ attention
• Stress ↑ weight loss, exaggerated ↑
hippocampal and hypothalamic IL-1β mRNA
expression in aged; exaggerated ↑
corticosterone in aged
• Higher hippocampal MHCII mRNA and IHC
staining in aged mice at baseline, and
increased in aged mice following stress

Table 1.1. Summary of animal studies comparing young and aged differences in
cognitive function following stress. Various models of stress and immune system
activation examined in young and aged animals show that aged animals have an
exaggerated neuroinflammatory response and prolonged behavioral deficits compared
to young animals.
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Peripheral infection may be modeled in rodents using intraperitoneal injections
of lipopolysaccharide (LPS), which is a component of the cell wall of gram-negative
bacteria and a potent stimulator of Toll-like receptor (TLR) 4 signaling. This model
rapidly induces a pro-inflammatory response. Additionally, some labs have begun
modeling infection with peripheral injection of Escherichia coli to control for weightdependent dosing, as aged mice are heavier and require larger quantities of LPS (102).
LPS can be injected peripherally and rapidly induces a neuroinflammatory response
with associated sickness behaviors in rodents, characterized by lethargy, reduced
activity, fever, and social withdrawal (108). This behavior is an evolutionarily preserved
response, as social withdrawal during infection is a protective mechanism to prevent
the spread of illness to others. This behavioral response may be in part due to the
elevated production of cytokines and systemic stress factors that enter the brain
parenchyma via the circumventricular organs or indirectly through activation of
endothelial cells and nearby perivascular macrophages. While this is a seemingly
positive protective mechanism, the CNS of aged animals respond in an exaggerated
manner to peripheral LPS injection, with higher immediate expression of proinflammatory genes and delayed behavioral recovery (99). This demonstrates that
aged microglia are “primed” to respond more robustly to a pro-inflammatory stimulus.
While the phenomena of microglia priming with age has been well-established,
the molecular mechanisms underlying this phenotype have only recently been
investigated. Recently, it was found that high mobility group box 1 (HMGB1) protein
levels are elevated in the hippocampi and cerebrospinal fluid (CSF) of aged rats.
HMGB1 is secreted by various immune cells including microglia as a danger signal
(102) and in turn stimulates cells via the TLR4 and receptor for advanced glycation
end-products (RAGE) receptors to activate pro-inflammatory gene expression.
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Blockade of HMGB1 with a pharmacological inhibitor, Box-A, was able to abrogate the
priming phenotype of microglia in aged rats in vivo through reductions of MHCII and
TLR4 expression in the hippocampus (102), two notable molecules up-regulated in
microglial priming. Treatment with Box-A also improved functional recovery in social
exploration tasks in aged animals (102) and enhanced freezing behavior in contextual
fear conditioning tests, showing an improvement in cognitive function (102). Further
work examining strategies to reverse the primed phenotype of aged microglia will
provide novel targets to reduce dysfunctional neuroinflammatory responses in the
elderly after neurological injury.

Aged microglia contribute to enhanced pathology following traumatic brain
injury (TBI):
Elderly patients are more vulnerable to traumatic brain injury (TBI), with a
doubling of TBI incidence every 10 years beginning at the age of 65, mostly related to
increased falls (109, 110). Age is an independent predictor for mortality after TBI (111,
112) and older patients that survive their injury have reduced functional recovery
compared to younger individuals (113, 114). Additionally, adults age 55 years or older
suffering a moderate to severe TBI or those 65 or older suffering a mild TBI have an
increased risk of developing dementia compared to younger patients (115). Together,
these clinical findings suggest that the brain becomes more sensitive to TBI as we age,
and that the pathological consequences of injury are much graver. Many factors
contribute to this age-related vulnerability including increased amyloid deposition (116),
however, it is not clear whether inflammation drives the exacerbation of injury or if it is
secondary or correlative to the increase in neuronal death seen in older individuals.
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TBI may be modeled in animals using a variety of methods (117–119). In
rodents administered a controlled cortical impact (CCI), microglia are activated and
express higher levels of pro-inflammatory genes and lower or undetectable levels of
anti-inflammatory genes even months after the initial injury, suggesting an overall shift
in microglia phenotype toward a pro-inflammatory status with time following TBI. Aged
mice that underwent CCI displayed higher MHCII expression (120) and had higher
expression of NADPH oxidase subunits p22phox and gp91phox Aged mice also had a
corresponding reduction in the expression of antioxidant enzymes superoxide
dismutase 1 (SOD1) and glutathione peroxidase 1 (GPX1) following TBI compared to
young mice, indicative of higher ROS production in aged mice. These results
corresponded with larger lesion volume and reduced cellular density in the
hippocampus and thalamus of aged mice 7 days after CCI (120). Together, these
results suggest that microglia in the aged brain are more detrimental in TBI and may
predispose the aged to impairments in phagocytosis and increased accumulation of
toxic waste products such as amyloid.
In addition to contributing to the excessive pro-inflammatory status in the aged
brain, microglia have been shown to be directly involved in post-TBI recovery, including
neurite outgrowth. Nogo receptor 1 (NgR1) signals through the RhoA-ROCK pathway
and results in the collapse of the growth cone of neurites (121). Thus, higher levels of
NgR1 are associated with reduced neurite outgrowth. NgR1 was found to be highly
expressed in Iba1+ microglia in the cortex and basal forebrain beginning at P1 and
declined until stable baseline adult levels were achieved by P21 (122). However,
expression levels were increased in mice at 17 months of age (122), suggesting that
aged microglia may predispose the aged brain to decreased neurite outgrowth
following an acute injury. In young animals with TBI from a stab wound model, the
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number of Iba1+ NgR1+ microglia increased relative to sham controls, although total
levels of NgR1 measured by Western blot did not increase 7 days post-injury (122).
However, given the different phenotype of microglia in the aging brain, future studies in
aged mice will be necessary to confirm the effects of elevated NgR1 in aged microglia
following TBI.
It is not difficult for one to imagine the synergistic effects of aging and a prior
TBI, as aging itself primes microglia in a similar manner as TBI. Thus, the response to
TBI in aged animals is noticeably worse, and the response of repetitive TBI in aged
animals is worse still. With the observation of increased incidence of TBI with each
decade of life after the age of 65, repetitive TBIs are not only more common, but the
consequences of each additional TBI are likely more severe than the previous TBI,
leading to progressive deficits and cerebral atrophy.

Aged microglia contribute to worse recovery and functional outcomes following
stroke:
Age is the leading non-modifiable risk factor for stroke. While preclinical studies
in animal models have mostly been performed in young animals, there are many
laboratories that are now transitioning their studies into aged animals. Popa-Wagner’s
group in particular has demonstrated profound changes in microglia activation after
stroke with age (123, 124). While more expensive and surgically challenging, this is an
increasingly important consideration as the response to stroke differs in young and
aged animals (18, 125, 126). Perhaps most importantly, aged animals have
comorbidities that resemble those seen in clinical populations, including obesity (127)
and hypertension. Thus, modeling stroke in aged animals allows for a more accurate
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modeling of stroke (124). However, variations in stroke models (e.g. transient vs.
permanent occlusion of vessels, time duration of infarction, age of “aged” animals,
strain of mice, etc.) make it difficult for laboratories from different groups to compare
studies.
Interestingly, despite the high level of cell death that occurs following cerebral
ischemia, one study reported that microglia have a more anti-inflammatory phenotype
with higher expression of CD206, IL-10, YM1/2, TGFβ, ARG1, and CCL22 in the first 3
to 5 days following stroke, with a transition to higher expression of pro-inflammatory
genes CD16, CD32, and iNOS at 7 and 14 days post-stroke (128). While this study
examined RNA expression from an entire stroke hemisphere, the phenotype of
microglia following stroke is likely influenced by their relative location to the infarcted
region where cell death and pro-inflammatory stimuli are abundant. However, these
authors found corresponding patterns of expression of CD16/32+ Iba+ and CD206+
Iba1+ microglia using immunofluorescence in the peri-infarct region of the stroke
consistent with their gene expression findings (128). The timing of phenotype switching
likely depends on the stroke model used, and the brain area assessed.
Similar findings were also found in aged animals, with higher Iba1+ CD206+
microglia peaking at 7 days post-stroke, and then transitioning to elevated Iba1+
CD16/CD32+ microglia at 14 days post-stroke (129). However, despite this pattern of
early anti-inflammatory polarization followed by delayed pro-inflammatory polarization
in both young and aged mice, aged mice had reduced anti-inflammatory polarization
relative to young animals (129). The authors also found a positive correlation between
the number of Iba1+ CD206+ microglia and improved cognitive and motor performance,
suggesting that the reduced ability of aged microglia to efficiently polarize to an antiinflammatory phenotype may be responsible for poorer functional recovery following
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stroke (129). However, the exact mechanism linking the inflammatory status of
microglia to functional outcomes remains to be elucidated.
As noted earlier, microglia of aged animals have reduced cellular motility and
phagocytosis, and augmented production of pro-inflammatory cytokines. These
baseline differences have implications for microglial activation after stroke. In a distal
MCAO (dMCAO) model of stroke, aging increased microglial proliferation in the periinfarct area (130). Additionally, while aging was not shown to reduce proliferation of
neuroblasts within the subventricular zone, there was an age-related reduction of
migration of these neuroblasts to the peri-infarct area (131). Perhaps the enhanced
proliferation of microglia (and astrocytes) in the peri-infarct area of aged animals is
detrimental to neuronal repair processes following stroke leading to worse behavioral
outcomes.
Interestingly, aging is associated with an accumulation of resident memory CD8
T cells in the brain parenchyma (42). At baseline, higher numbers of CD8 T cells
correlate with reduced pro-inflammatory functions of microglia in the aged brain;
however, following tMCAO these CD8 T cells had increased TNF, IFNγ and CCL2 as
determined by intracellular cytokine staining (42). Together, these results suggest that
CD8 T cells within the aging brain modify microglia homeostasis under naïve conditions
but may be another source of priming the aging brain and potentiating damage
following tMCAO. The role of these resident memory CD8 T cells in the aging brain will
need to be evaluated in other disease models to determine their importance and
relevance to disease.
It has also become increasingly apparent that inflammatory changes following
ischemic stroke are not limited to the CNS but are evident throughout the body,
including peripheral immune organs like the spleen. Following tMCAO both young and
33

aged mice have elevated gut permeability and translocation of intestinal microbes, but
aged mice had prolonged loss of body weight, severe hypothermia, and persistent
elevation of plasma IL-6 production at 72 hours post-stroke indicating that aged
animals were not able to resolve the infection (132). While not directly assessed in this
study, bacterial byproducts themselves (e.g. LPS) may be elevated in the blood of aged
mice following stroke and, given the increased level of blood-brain barrier breakdown
after ischemic injury, may directly activate microglia and further potentiate the proinflammatory polarization of microglia in the aged brain. Further studies investigating
these mechanisms are necessary to understand how peripheral factors could influence
microglia polarization and function, both under healthy conditions and in response to
injury and disease.

The role of aged microglia in Alzheimer’s disease:
Alzheimer’s disease (AD) is a neurodegenerative disease primarily affecting
older individuals and is the most common cause of dementia (133, 134). The earliest
clinical manifestation of AD is memory impairment, and this is usually present at the
time of clinical presentation/diagnosis of the disease. Currently available treatments
only target the symptoms of AD, as there are no disease-modifying therapies available
for the treatment of AD. New therapeutic approaches include vaccines targeted
against Aβ and infusions of antibodies targeting Aβ such as Bapineuzumab; however,
these approaches have failed in clinical trials to improve clinical outcomes (135)
despite being well-tolerated by patients (136–138). While these results were
disappointing, there is renewed hope in the clinical effectiveness of aducanumab, an
antibody that selectively targets aggregated Aβ which appears to show promise in
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preclinical studies and clinical trials (139). However, even if these new biological
therapeutics slow or even halt the progression of AD, aged patients have other
etiologies for cognitive decline beyond amyloid-beta pathology, such as vascular
dementia, for which these drugs are likely to be less effective.
The AD brain has many specific pathological findings (140). These include
aggregations of Aβ, hyperphosphorylated tau, neurofibrillary tangles, and glial cell
activation. While the exact cause of Alzheimer’s disease pathogenesis remains
debatable, it is becoming clear that microglia play a crucial role in disease pathology,
which has been recently reviewed elsewhere (141–143). The hippocampus is the area
of the brain most densely populated by microglia, and is also one of the brain regions
that is affected early in AD and leads to many of the clinical symptoms (38, 134, 144).
The exact trigger for microglia activation remains unclear, but Aβ itself is capable of
directly activating microglia (145–147). Accumulation of extracellular Aβ may be due to
impaired phagocytosis of abnormal proteins by aged microglia. Aged microglia have
poorer phagocytosis compared to microglia from young mice (18), potentially leading to
accumulation of Aβ in the extracellular environment, further formation of Aβ
aggregates, and a subsequent further activation of microglia (64, 148).
The reduced ability of microglia to phagocytose Aβ may be due to a decreased
ability of microglia to directly bind and degrade Aβ. One study specifically comparing
phagocytosis of Aβ by microglia in young and aging PS1-APP mice found that
microglia from 8-month-old PS1-APP mice demonstrated significantly reduced RNA
expression of Aβ binding receptors SRA, CD36, and RAGE relative to age-matched
wildtype littermates, and levels declined even further by 14-months of age (149).
Furthermore, reduced expression of Aβ degrading enzymes insulysin, neprilysin, and
MMP9 was seen by 14-months of age (149). These findings suggest that in the setting
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of AD, microglia become increasingly inefficient at their ability to clear Aβ with age,
highlighting yet another functional failure of aged microglia.
The inflammatory nature of aged microglia likely also plays a role in AD
pathogenesis. Microglia in naïve wildtype aged mice express elevated levels of IL-1β
and TNF (18) compared to young microglia, suggesting that the pro-inflammatory
“activated” phenotype occurs in the absence of AD or any other pathology and are a
hallmark of aging in the CNS. In the setting of AD pathology, microglia PS1-APP mice
were found to have elevated RNA expression of IL-1β and TNF at 8-months of age with
further elevation in expression by 14-months (149). N9 microglia cells treated with TNF
were found to have decreased expression of phagocytic receptors SRA and CD36, and
in turn also had decreased uptake of Aβ (149). This suggests that elevation of
inflammation from microglia within the aging brain reduces their ability to effectively
phagocytose Aβ, thereby contributing to the pathogenesis and/or progression of
Alzheimer’s disease.
Recently, experiments have been performed using plasma transfers and
parabiosis models to examine the contribution of peripheral cells and circulating factors
in AD pathology, as summarized in Table 2.
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Study
(150)

Strain
APP on
C57Bl/6
background

Age(s)
Young 2-3m
Aged 16-20m

Model
Heterochronic
parabiosis
• Aged APP –
Young WT
• Aged APP –
Aged APP
• Aged WT –
Aged WT
Plasma transfer
• PBS
• Young plasma

Duration
5 weeks

Notable findings
• In the hippocampus: rejuvenation of
synaptophysin and calbindin
immunoreactivity; no change in total Aβ
or Aβ-42 levels; no effect of CD68
immunoreactivity

Administration
twice weekly
for 4 weeks

• In the hippocampus: rejuvenation of
synaptophysin and calbindin
immunoreactivity; no effect of CD68
immunoreactivity
• Improved memory, spatial learning
memory with young plasma transfer
In heterochronic Tg parabionts:
• ↓ Aβ-40, Aβ-42, total Aβ, and Congo
Red plaques in brain
• ↓ CAA vessel number and area
• Alleviation of neuronal degeneration
and apoptosis

(151)

APPswe/PS1d
E9 Tg

Young 3m
Tg 3m

Heterochronic
parabiosis
• Young Tg –
Young WT
• Age-matched Tg
• Age-matched
WT

6 months

(152)

B6.CD45.1
5XFAD
(CD45.2)

4m or 8m

Parabiosis
B6.CD45.1 5XFAD

4 weeks

B6.CD45.1
APP-PS1
(CD45.2)

3.5m

Parabiosis
B6.CD45.1 - APPPS1

9 weeks

• No recruitment of CD45.1 WT
monocytes to brains of 5XFAD
parabionts
• Brain-resident microglia associate with
amyloid plaques, not peripheral
monocytes
• No recruitment of CD45.1 WT
monocytes to brains of APP-PS1
parabionts

Table 1.2: Summary of studies examining the role of the peripheral immune
system on AD pathology. Recent experiments utilizing models of parabiosis and
plasma transfers are beginning to address the role of and extent that the peripheral
immune system and soluble plasma factors may be manipulated in modifying AD
pathology and cognition.
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The most recent study utilized a model of heterochronic parabiosis to explore
the possibility that circulating factors in young blood may prevent AD pathology and
progression. Heterochronic parabiosis is a model in which a young animal is surgically
attached to an aged animal and through anastomoses of the wound healing process
come to share a common blood supply. This model has been shown to have
significant effects on neurogenesis and identified circulating molecular markers of
aging, particularly CCL11 and β2-microglobulin (83, 153). Heterochronic parabiosis
with young 2-3-month-old wildtype mice and old 16-20-month-old APP transgenic mice
showed that after 5 weeks of shared circulation, no reduction in total Aβ or Aβ-42 was
seen in the hippocampus of aged APP heterochronic mice compared to APP isochronic
mice (150). Interestingly, there was no difference in CD68 immunoreactivity (a
lysosomal protein enriched in myeloid cells including microglia (154)) in the hippocampi
of these mice, suggesting that once pathology is established the potential for reducing
progression or reversing plaque burden may be limited. However, despite the inability
of heterochronic parabiosis to delay or reverse disease pathology, APP mice had
increased synaptophysin and calbindin immunoreactivity in the hippocampus,
suggesting that circulating factors in young blood may at least be able to restore
synaptic protein levels despite a lack of reduction in total Aβ or Aβ-42 plaque levels
(150). While behavioral outcomes cannot be assessed in parabionts due to the
surgery, these may be more accurately assessed in similar studies using plasma
transfer experiments (83, 153). Similar to heterochronic parabionts, APP mice
receiving blood from young wildtype donors also demonstrated increased
synaptophysin and calbindin immunoreactivity relative to APP mice receiving PBS.
APP mice receiving plasma from young wildtype donors were shown to have improved
performance on Y-maze and contextual fear conditioning tests (150). Together, these
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results suggest that factors from young healthy donors may be able to improve
functional performance in diseased animals despite the inability to delay or reverse
disease progression. Further investigation of potential “rejuvenation factors” in young
plasma will be necessary to determine which factors may be responsible for these
changes.

Epigenetic regulation of microglia polarization
As microglia are cells poised to respond to changes in their environment,
determination of the overall phenotype of microglia is multifactorial and complex.
Numerous environmental factors play a role. More specifically, damage associated
molecular patterns (DAMPs), pathogen associated molecular patterns (PAMPs), ionic
imbalances, and signals through various Toll-like receptors (TLRs) are all
independently capable of initiating signaling cascades.
Additionally, while microglia phenotypes were initially believed to be analogous
to those of peripheral macrophages of the hematopoietic myeloid lineage, it has been
more recently believed that microglia phenotypes should not be thought of as mutually
exclusive pro-inflammatory or anti-inflammatory phenotypes. Instead, many authors
believe that microglia should be defined by the inciting stimulus to allow the scientific
community to interpret results appropriately (155). Such definitions of specific stimuli,
concentrations, or design and duration of exposures in vivo will allow for others to
interpret and replicate the results (155, 156).
Depending on the signaling molecules present and the amount likely determine
the overall phenotype of microglia. Thus, if predominantly TLR4 signaling molecules
are present in the surrounding microenvironment, those microglia will be predominantly
pro-inflammatory. However, if a mixture of pro- and anti-inflammatory signaling
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molecules are simultaneously present in the microenvironment (which is more
indicative of what occurs in the in vivo environment) a single microglia cell may
simultaneously express both pro- and anti-inflammatory genes. However, the overall
phenotype of microglia may be generalized by examining the levels of common
markers of both pro- and anti-inflammatory phenotypes.
However, while the more realistic polarization of microglia occurs in vivo, the
need to manipulate the microenvironment to elicit precise conditions is ideal for
studying molecular mechanisms in vitro. While a number of stimuli may be used to
manipulate the microenvironment, lipopolysaccharide (LPS) and interferon (IFN)-γ are
commonly used in combination to stimulate a pro-inflammatory phenotype polarization
whereas interleukin (IL)-4 is used to stimulate an anti-inflammatory phenotype (155).
Using these conditions, one may specifically isolate microglia and polarize their
phenotypes to better understand the molecular mechanisms of microglia phenotype
polarization.
Epigenetic regulation is becoming increasingly implemented in the regulation of
phenotype polarization of T cells (157, 158), B cells (159–162), and more recently
identified in macrophages and microglia (61, 163–168). The term “epigenetics” is
derived from Greek, and in translation means “above the gene.” As such, epigenetics
refers to the study of changes in gene expression that occur outside of the DNA
sequence itself, and include methods of modifying the physical chromatin structure
which may allow for transcriptional activation or suppression (169). Understanding the
role of epigenetic regulation in microglia phenotype polarization is particularly intriguing
because many times a single epigenetic regulator may simultaneously regulate the
expression of sets of genes (163, 169, 170). Thus, the potential to target one molecule
to control the expression of an entire phenotype is particularly attractive.
40

There are many elements to epigenetic regulation, including methylation of DNA
strands themselves, modifications of histone tails, and nucleosome positioning. The
modification of histone tails provides an elaborate “histone code,” allowing cells to gain
control of their gene expression over a wide range of conditions (169, 171, 172).
However, as each nucleosome can be composed of various types of histones, and
each histone tail may have numerous modifications simultaneously, understanding the
effective summation of various combinations of modifications in various specific cell
types is only beginning to be understood.
Recently it was discovered that epigenetic regulation plays an essential role in
microglia polarization. Tang et al discovered that Jumonji Domain Containing 3 (Jmjd3)
was essential to microglia anti-inflammatory polarization (163). Jmjd3 is a histone
lysine demethylase that specifically removes methyl groups from transcriptionally
repressive histone H3 lysine 27 trimethylation (H3K27me3) marks to monomethylation
marks (H3K27me1) (173). The histone modification H3K27me1 established by Jmjd3
allows for transcriptional activation (173). Tang et al found that when Jmjd3 was
inhibited there was a significant reduction in H3K27me1 levels at the promoter of Irf4, a
transcription factor heavily involved in microglia anti-inflammatory polarization (163,
174, 175). Furthermore, inhibition of Jmjd3 they found a significant reduction in the
expression of Irf4 (163). These authors concluded that Jmjd3 is essential for microglia
to fully polarize to an IL-4-induced anti-inflammatory phenotype (163).
Interestingly, contrasting the enzymatic effects of Jmjd3 is Enhancer of Zeste
Homologue 2 (Ezh2). Ezh2 is a histone lysine N-methyltransferase that establishes
H3K27me3 marks (176). This particular histone modification represses gene
transcription by condensing the chromatin structure and preventing RNA Polymerase II
and transcription factors from interacting with promoters (176–178). As Ezh2 and
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Jmjd3 perform antagonizing functions, we hypothesize that while Jmjd3 is essential for
anti-inflammatory polarization that Ezh2 may be essential for pro-inflammatory
polarization (Fig. 1.5).
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Figure 1.5. Functional epigenetic antagonism of Ezh2 and Jmjd3. Ezh2 deposits
methyl groups to establish H3K27me3 marks, leading to compaction of chromatin and
displacement of RNA Polymerase II transcription complex to repress gene
transcription. In contrast, Jmjd3 demethylates H3K27me3 marks to H3K27me1 which
allows for chromatin relaxation and the ability for RNA Polymerase II complex to
activate gene transcription.
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As discussed above, microglia phenotype changes drastically with age and
acquires a pro-inflammatory phenotype at baseline. Additionally, we understand that
epigenetic regulation plays a significant role in microglia polarization. We hypothesize
that peripheral factors in aged mice are responsible for increasing Ezh2 function in the
brain with age, causing the aged brain to acquire a dysfunctional pro-inflammatory
aged phenotype. We further hypothesize that these epigenetic modifications, which by
definition are reversible, may be rejuvenated through manipulation of the circulating
peripheral immune system.

Conclusion
The U.S. population is aging at an alarming rate and the increase in age-related
diseases such as stroke, TBI, and Alzheimer’s disease will place an increasing strain
on our healthcare system. Chronic age-related increases in inflammation exist in both
the periphery and CNS. Microglia, like other long-lived cells may be especially
vulnerable to the detrimental effects of aging, as reflected by changes in their molecular
and cellular phenotype, decreased phagocytic potential, and increased production of
ROS. These pro-inflammatory and primed microglia play a substantial role in the
pathogenesis and progression of age-related neurological diseases and in the
exaggerated response to injury and infection seen in the aged. Understanding the
mechanisms by which microglia age will enhance the identification and development of
novel intervention strategies to reduce the burden of age-related neurological diseases.
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Chapter 2:
Materials and Methods
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Mice
All animal experiments and terminal endpoints were conducted in compliance with
approved protocols from the Institutional Animal Care and Use Committee of the
University of Texas Health Science Center. Animal numbers of each group were
calculated by power analysis and animals were randomly assigned to each group
where applicable. All animals were either bred in-house or were allowed to rest for at
least one month prior to experimentation. For naïve aging studies, C57Bl/6 mice at 3-,
6-, 12- (Charles River), 18-, or 24-months of age (NIA) were used. For parabiosis
surgeries, young 2- to 3-month-old GFP mice (C57BL/6-Tg(UBC-GFP)30Scha/J, Stock
004353, Jackson Labs) or wildtype C57Bl/6 mice (Charles River) were used, as well as
aged 18- to 20-month-old wildtype C57Bl/6 mice (NIA). For primary microglia cell
culture, C57Bl/6 (Charles River) P0.5-P3 mouse pups were used. Sex was determined
using the black dot method and confirmed with DNA from tail snips. Tails were
genotyped for SRY, the male-specific testis determining gene, and MYOG was used as
a positive PCR genotype control.

Parabiosis Surgery
For parabiosis surgeries, pairs consisted of young (2- to 3-month) GFP and young WT
(young isochronic), young GFP and aged (18- to 20-month) WT (NIA) (heterochronic),
and aged WT and aged WT (aged isochronic). Parabiosis was performed as
previously described with some modifications (83, 179) . Briefly, animals were
randomly assigned to surgical groups and pair-housed 1 pair per cage for at least 1
week prior to surgery. Pairs noted to have excessive fighting were excluded from the
study. Mice were anesthetized with isoflurane, ophthalmic ointment was applied, and
mice were administered slow-release buprenorphine pre-operatively (Buprenorphine
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SR-LAB, 1mg/mL, 5mL, ZooPharmBZ8069317). Fur of adjacent surgical sides was
clipped. Mice were transferred to a disinfected surgical station where they were
aseptically prepared. Identical skin incisions were made on opposing flanks from the
olecranon, along the length of the side, to the just anterior to the patella. 4-0 nylon
sutures (Ethicon) were used to secure the humerus and femur of parabionts. Skin flaps
of parabionts were joined using 6-0 Vicryl sutures (Ethicon) with simple continuous
stitching. Prior to final skin closure, wounds were flushed with 5mL sterile saline.
Stitches were secured with 9mm wound clips (Reflex) placed at regular intervals. In
our model design, parabionts were not administered antibiotics in an attempt to
maintain the integrity of the intestinal microbiome. Pairs were administered 1mL of
sterile saline subcutaneously for 7 days following surgery, and were given softened
food in their cages. Paired weights were monitored daily for 7 days, and then twice a
week thereafter. Chimerism was confirmed by cheek bleed and analysis of percent
GFP+ cells by flow cytometry after 2 weeks. This control was not possible for aged
isochronic pairs as aged GFP mice are not commercially available, although others
have reported efficient chimerism in aged isochronic pairs (180). Pairs were humanely
euthanized after 8 weeks and samples were collected for further analysis.

Multiplex cytokine analysis
Deeply anesthetized mice were perfused with ice-cold 1X PBS and whole hemispheres
were extracted and flash frozen. Tissue samples were homogenized in NP-40 lysis
buffer (Thermo Fisher) and sonicated for 6 cycles of 5” on, 5” off on ice at 60%
amplitude (QSonica). Lysates were centrifuged for 20 minutes at 4°C, 28,000rpm
(Thermo Fisher). Supernatants were aliquoted and frozen at -80°C. Samples were
thawed once for use in assays. Protein concentration was determined by BCA
47

(Thermo Fisher). The following multiplex immunoassays were used: Bio-Plex Pro
Mouse Chemokine 33-plex Assay (Bio-Rad, 12002231), Bio-Plex Pro Mouse Cytokine
23-plex Assay (Bio-Rad, M60009RDPD), Bio-Plex Pro Mouse Cytokine Group II 9-plex
Assay (Bio-Rad, MD000000EL), Bio-Plex Pro Mouse Cytokine Group III 8-plex Assay
(Bio-Rad), Bio-Plex Pro Mouse TGFβ 3-plex Assay (Bio-Rad, 171W4001M), Milliplex
MAP Mouse Kidney Injury Magnetic Bead Panel 2 (MKI2MAG-94K, Millipore), Milliplex
MAP Mouse MMP Magnetic Bead Panel 3 (MMMP3MAG-79K, Millipore), Milliplex MAP
Mouse Angiogenesis/Growth Factor Magnetic Bead Panel (MAGPMAG-24K, Millipore),
Milliplex MAP Mouse Soluble Cytokine Receptor Magnetic Bead Panel (MSCRMAG42K, Millipore). Samples were run in duplicate and assays were performed according
to the manufacturer’s protocols with some minor modifications. Assays were analyzed
using a Bio-Plex 200 (Bio-Rad) with a minimum of 50 beads per bead region required
for a valid read. Samples with a percent coefficient of variation >15% were excluded
from analysis.

Primary microglia culture
P0.5-P3 mouse pups were humanely euthanized on ice and brains were removed for
dissection. Cortices were isolated and enzymatically digested in 1.5mL sterile tubes
using an enzymatic digestion kit (Neural Dissociation Kit (P), Miltenyi Biotec). Cortices
were homogenized using sterile 1000uL and then 200uL pipet tips (USA Scientific).
Individual cortices were plated in 25cm2 flasks (Falcon) coated with poly-D-lysine
(PDL)-coated (Millipore) in 4mL of media and cells were allowed to adhere overnight.
To study sex differences, cells were cultured in Sex Differences Murine Microglia Media
(SD mMG Media: phenol red-free DMEM (Gibco), 10% charcoal-stripped fetal bovine
serum (Sigma), glutamine (Gibco), and 1% penicillin / streptomycin (Gibco). After 24hr
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media was aspirated, adherent cells were gently rinsed in 1mL of media to remove
debris, and 4mL of fresh media was added. On day in vitro (DIV) 5 and DIV 10, L929
conditioned media was added to 30%. On DIV 14, cultures were supplemented with
HEPES and sodium bicarbonate to maintain pH while shaking at 150rpm for 2-3 hours
on a 37°C incubated shaker. Microglia were counted and plated at 60-80,000 cells /
well of PDL-coated 24-well plates (Corning) in L929 conditioned microglia media and
allowed to rest for at least 2 days prior to experimentation.

BV-2 microglia cell culture
BV-2 murine microglia cell line cultures were maintained in Dulbecco’s Modified Eagle’s
Medium, 10% heat-inactivated fetal bovine serum, and 1% penicillin / streptomycin
(Gibco).

L929 conditioned media
L929 cell line (ATCC) were cultured to full confluency on 75cm2 flasks (Corning) in
DMEM, 10% heat-inactivated FBS, 1% penicillin / streptomycin. Media was removed,
cells were rinsed in SD MMG Media, and then cultured in 35mL of SD mMG Media.
After 2 weeks, L929 conditioned media was collected, filtered, and frozen at -80°C.

Stimulation of primary microglia with young or aged murine plasma
Primary microglia were obtained and cultured as above. Plasma was isolated and
pooled from 3 healthy male C57Bl/6J mice of 3 months or 18 months of age. SD mMG
media was prepared substituting 10% FBS with 10% murine plasma, and cultures were
stimulated for 96 hours before isolating cells for RNA for RT-PCR analysis as described
below.
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RNA Isolation and Reverse Transcription PCR (RT-PCR)
For RT-PCR analysis, RNA was isolated using the RNEasy Micro Plus kit (Qiagen)
RNEasy Lipid Mini Kit (Qiagen) and RNA purity was assessed by Nanodrop (Thermo).
RNA was DNase-treated (NEB) and cDNA and no reverse transcriptase controls were
prepared using iScript cDNA Synthesis Kit (Bio-Rad). Samples were diluted and
PrimePCR Arrays (Bio-Rad) were performed according to the manufacturer’s
instructions using (Supermix name) Bio-Rad on a CFX384 Touch (Bio-Rad). Genes of
interested were validated by individual real-time PCR (RT-PCR) using (Supermix
name) (Bio-Rad) on a CFX96 Touch or CFX384 Touch (Bio-Rad). Primer sequences
were designed using the PrimerQuest Tool available from IDT DNA
(https://www.idtdna.com/Primerquest/Home/Index) with attempts to design primer pairs
around exon boundaries. Sequences were validated and are listed in Table 2.1. Data
was analyzed using the ΔΔCt method.
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Target

Forward primer

Reverse primer

Accession

Il1b

GGCAGGCAGTATCACTCATT

GAGGATGGGCTCTTCTTCAAA

NM_008361

Il6

AGGAGACTTCACAGAGGATACC

GAATTGCCATTGCACAACTCTT

NM_031168

Tnfa

CCTCTTCTCATTCCTGCTTGT

TGGGAACTTCTCATCCCTTTG

NM_019467

Nos2

CCACAGTCCTCTTTGCTACTG

TGCAGACAACCTTGGTGTT

NM_010927

Arg1

CACCCTGACCTATGTGTCATTT

TCTGGGAACTTTCCTTTCAGTTC

NM_007482

Aif1

GAAGCCTTCAAGGTGAAGTACA

TTCAGCTCTAGGTGGGTCTT

NM_019467

Itgam

CCGGAAAGTAGTGAGAGAACTG

ATCCAAGGGATCACCGAATTT

NM_001082960

Table 2.1. RT-PCR primers used for gene expression analysis.
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Western Blotting
Protein samples were prepared using Lamelli buffer (Bio-Rad) supplemented with betamercaptoethanol, heated, and loaded onto 4-15% TGX polyacrylamide gels (Bio-Rad)
and transferred onto PVDF (Bio-Rad). Blots were blocked using 5% milk in TrisBuffered Saline with Tween-20 (TBS-T). Blots were probed with anti-histone H3
(Abcam), anti-beta-actin-HRP (Sigma), anti-H3K27me1 (Millipore), anti-H3K27me3
(Millipore), anti-Jmjd3 (Abcam), anti-Ezh2 (Cell Signaling). Horseradish peroxidaseconjugated secondary antibodies were used to detect primary antibodies (Vector Labs).
Images were taken using a (Bio-Rad G-box) (Bio-Rad). Selected images were
quantified using Image Lab (Bio-Rad, Version 5.2.1).

Statistics
Statistics are presented as mean ± standard error of the mean (SEM) for all experiments
using Prism 7 (GraphPad). Interval power analysis was performed to determine group
size.

For comparisons between 2 groups, Student’s t-test was performed.

For

comparisons of multiple groups in naïve aging experiments, one-way ANOVA was
performed using the youngest 3-month-old animal group as a control group. If an
interaction was statistically significant, then Dunnett post-hoc test was performed. For
comparisons involving multiple groups in heterochronic parabiosis experiments, two-way
ANOVA was performed. If an experiment was found to be statistically significant, then
Tukey post-hoc test was performed. For evaluation of mortality and weight loss of our
model of parabiosis, log-rank Mantel Cox analysis was performed.
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Chapter 3:
The Aging Brain is Epigenetically Dysregulated
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Rationale
Other labs have shown that the histone demethylase Jmjd3 is essential for microglia
anti-inflammatory polarization by demethylating H3K27 modification to a
transcriptionally active H3K27me1 modification (163, 173). However, Ezh2 is a histone
lysine N-methyltransferase which performs opposing functions to Jmjd3 by establishing
transcriptionally repressive H3K27me3 histone modifications (176). Dr. Rodney Ritzel
from our laboratory has shown that microglia become more pro-inflammatory in the
brain with age (181). We hypothesized that Ezh2 function may be enhanced in the
brains of mice with age and may be associated with the pro-inflammatory phenotype of
the naïve aged brain. We first investigated the brains of aged mice to determine if the
brain becomes epigenetically dysregulated with age.

Ezh2 and Jmjd3 become imbalanced in the brain with age
To investigate if levels of Ezh2 and Jmjd3 change in the brain with age, we analyzed
protein levels of Ezh2 and Jmjd3 relative to β-actin by Western blot in whole murine
brains at 6, 12, 18, and 24 months of age (Fig. 3.1). Relative to 6-month-old mice,
Jmjd3 was significantly decreased by 12 months and remained decreased at 18 and 24
months (Fig. 3.1B). Ezh2 decreased by 12 months but levels of Ezh2 at 18 and 24
months of age were not significantly different from the levels of 6-month-old mice (Fig.
3.1C). Additionally, as Ezh2 and Jmjd3 perform antagonizing functions, we analyzed
the ratio of Ezh2 levels relative to Jmjd3 levels. Our analysis revealed that Ezh2 was
significantly elevated relative to Jmjd3 by 18 months and remained increased at 24
months (Fig. 3.1D). Additionally, the ratio of Ezh2:Jmjd3 demonstrated a progressive
stepwise increase with age (Fig. 3.1D). Furthermore, the level of Ezh1 does not
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change with age (Fig. 3.2). These findings suggest that the brain becomes
epigenetically dysregulated in regards to Ezh2 and Jmjd3 with age.
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Figure 3.1. Jmjd3 decreases with aging and results in an increased Ezh2:Jmjd3
ratio with age. (A) Western blot of Whole brain protein extracts of naïve 6-, 12-, 18-,
and 24-month-old male mice of Jmjd3, Ezh2, and β-actin loading control
immunoreactivity. Quantification of Jmjd3 (B), Ezh2 (C), and calculated ratio of
Ezh2:Jmjd3 quantification (D). Data are presented as the mean +/- SEM, one-way
ANOVA with Dunnet post-hoc test, n = 6/group, * p<0.05, ** p<0.01, *** p<0.005, ****
p<0.001.
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Figure 3.2. Ezh1 levels do not change in the brain with age. Western blot of Whole
brain protein extracts of naïve 6-, 12-, 18-, and 24-month-old male mice of Ezh1 and βactin loading control immunoreactivity. Quantification of Ezh1 relative to β-actin. Data
are presented as the mean +/- SEM, one-way ANOVA with Dunnett post-hoc test, n =
6/group, n.s. not significant.
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H3K27me3 and H3K27me1 become imbalanced in the brain with age
We then examined the levels of the histone modifications established by Ezh2 and
Jmjd3, H3K27me3 and H3K27me1, respectively. Western blot analysis of whole brain
murine protein samples revealed that with age mice undergo a decrease in H3K27me3,
H3K27me2, and H3K27me1 relative to total histone H3 (Fig. 3.3). The levels of
H3K27me3 and H3K27me1 correspond with the changes in the levels of Ezh2 and
Jmjd3, respectively. Analysis of the ratio of H3K27me3:H3K27me1 demonstrates that
the amount of H3K27me3 relative to H3K27me1 significantly increases by 18 months
and remains elevated at 24 months (Fig. 3.3). Together, these results suggest that the
brain becomes epigenetically dysregulated with age.
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Figure 3.3. The brain becomes epigenetically dysregulated with age. Western
blot of whole brain protein extracts of naïve 3- and 18-month-old male mice for
H3K27me3, H3K27me1, and H3 total loading control. Quantification of H3K27me3,
H3K27me1, and calculated ratio of H3K27me3:H3K27me1. Data are presented as the
mean +/- SEM, Student’s t-test, n = 3/group, * p<0.05.
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The brain becomes progressively inflammatory with age
To examine if the baseline inflammatory status changes in the brain with age, we
examined whole brain protein extracts of 3-, 6-, 12-, 18-, and 24-month-old mice by
multiplex cytokine analysis. Analysis revealed that the levels of 24 cytokines,
chemokines, and other analytes begin to be elevated at 6 months of age and
progressively accumulate at 12, 18, and 24 months of age (Fig. 3.4A). Additionally,
within our data analysis, we found it particularly notable that IFNγ and GM-CSF, which
are implicated in the primed phenotype of microglia, were found to be significantly
elevated in the brain with age (Fig. 3.4B, 3.4C). Overall, this analysis demonstrates
that the brain acquires an inflammatory status that progressively increases with age
and may promote a primed phenotype of microglia with age.
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Figure 3.4. Age-associated increase in inflammatory cytokines in the naïve
murine brain. (A) Whole brain extracts were examined in the brains of naïve mice at
3, 6, 12, 18, and 24 months of age by multiplex cytokine analysis. Each circle
designates the age of the mice examined, and the analytes significantly elevated at that
age are present in the circle and remain significantly elevated at later ages. The
individual plots for IFNγ (B) and GM-CSF (C) are shown. Data are presented as the
mean +/- SEM, one-way ANOVA with Dunnett post-hoc test, n = 5-9/group, * p<0.05, **
p<0.01, *** p<0.005.
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The circulating peripheral factors
We wanted to examine if the circulating peripheral factors also increased in naïve mice
across the healthy aging lifespan. We isolated plasma from naïve 3-, 6-, 12-, 18-, and
24-month-old mice and examined levels of circulating peripheral factors by multiplex
cytokine ELISA analysis. We found a that mice demonstrate a significant increase in
CXCL13, CCL11, CX3CL1, monocyte chemoattractant proteins MCP-3 and MCP-5,
and macrophage inflammatory proteins MIP-1α, MIP-2, and MIP-3α. Notably, our
results independently replicate those of the Wyss-Coray laboratory which found an
increase in circulating CCL11 with age (180). Moreover, our results also demonstrate
that circulating IFNγ does not increase with age, and levels of circulating GM-CSF were
undetectable. This suggests that the age-associated increase of these two cytokines
observed in the brain are not directly due to increased circulating levels of these
factors.
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Figure 3.5. Increase in circulating plasma factors with age. Multiplex cytokine
ELISA analysis of plasma isolated from naïve 3-, 6-, 12, 18-, and 24-month old mice.
Significant results were found for elevations in circulating (A) CXCL13, (B) CXCL1, (C)
CCL11, (D) MIP-1α, (E) MIP-2, (F) MIP-3α, (G) MCP-3, and (H) MCP-5. Levels of IFNγ
(I) were not significantly different from levels at 3 months of age. Data are presented as
the mean +/- SEM, one-way ANOVA with Dunnett post-hoc test, n = 5-9/group, *
p<0.05, ** p<0.01.
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The aged hippocampus has elevated expression of Aif1 and Itgam
Iba1 and CD11b and encoded by genes Aif1 and Itgam, respectively, and in the
absence of injury and peripheral cellular infiltration are two microglia-specific genes.
Age-associated microglia priming is associated with up-regulation of both Aif1 and
Itgam. We found that the expression of Aif1 and Itgam increase in the hippocampus of
mice with age (Fig. 3.6). This further supports our observation that the aged brain
becomes progressively inflammatory with age.
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Figure 3.6. Aif1 and Itgam expression increases in the hippocampus of naïve
mice with age. RT-PCR analysis using the ΔΔCt method for Aif1 and Itgam
expression in the hippocampus of naïve mice at 6 and 24 months of age. Data are
presented as the mean +/- SEM, Student’s t-test, n = 6-8/group, * p<0.05, ** p<0.01.
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Aged plasma factors directly influence microglia phenotype in vitro
To determine if peripheral factors can influence microglia phenotype, we cultured
primary microglia cultures using plasma isolated from young 3-month-old or aged 18month-old mice. We found that the microglia stimulated with aged plasma
demonstrated up-regulation of pro-inflammatory genes Il1b and Il6, but not Tnfa (Fig.
3.7). This demonstrates that an aged plasma factor(s) may be directly responsible for
influencing a pro-inflammatory phenotype microglia in the brain with age.
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Figure 3.7. Aged plasma increases expression of Il1b and Il6 in primary
microglia in vitro. Primary microglia were cultured in serum-free media containing
plasma isolated from young 3-month-old or aged 18-month old male mice. RT-PCR
analysis using the ΔΔCt method was performed. Data are presented as the mean +/SEM, Student’s t-test, n = 4/group, * p<0.05.
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Conclusions
This work provides valuable insight into how the brain and periphery change with
healthy aging in the absence of any inciting stimulus. First, this data demonstrates that
the brain becomes epigenetically dysregulated and pro-inflammatory with age. The
aged brain exhibits higher levels of ratio of Ezh2:Jmjd3 and corresponding increase in
H3K27me3 and decrease in H3K27me1 with age. Additionally, the brain becomes
more pro-inflammatory with age and increases progressively throughout the lifespan of
the healthy naïve mouse. This suggests that the aging process is cumulative and
consistently progresses with time. Additionally, our corresponding studies of aging
plasma demonstrates that some factors increase in the circulating periphery with age,
but these do not directly reflect those that increase in the brain. Of those elevated in
the circulating periphery, notably macrophage inflammatory proteins and monocyte
chemoattractant proteins, suggests a progressive inflammatory environment. However,
levels of major pro-inflammatory cytokines were not significantly elevated. For
example, levels of IL-1β, IL-6, and TNF-α were not significantly elevated in the
circulating plasma with age. When examining the plasma and brain multiplex cytokine
ELISA data together, this suggests that the pro-inflammatory environment of the aging
brain is potentially an independent inflammatory process and not reflective of ongoing
systemic inflammation.
Furthermore, we questioned whether circulating peripheral factors may influence
the inflammatory phenotype of the aging brain. We cultured primary microglia and
stimulated cells with plasma isolated from naïve young or aged mice. Of those cultured
with plasma from aged animals, there was increased expression of pro-inflammatory
Il1b and Il6. This suggests that circulating peripheral factors may directly influence the
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phenotype of the aged brain. Together, this work demonstrates that there is an
imbalance in epigenetic regulation between Ezh2 and Jmjd3 and this is accompanied
by a significant transition of the aged brain to a pro-inflammatory phenotype.
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Chapter 4:
Ezh2 is Essential for Pro-Inflammatory Microglia Polarization
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Rationale
Being the resident innate immune cells of the central nervous system, microglia
have the potential to initiate immune responses through polarization of their phenotype.
While multiple phenotypes have been characterized in response to particular stimuli,
the two predominant phenotypes are the pro-inflammatory and anti-inflammatory
phenotypes. As we age, Dr. Rodney Ritzel from our laboratory has shown that
microglia in the brains of aged mice become more pro-inflammatory at baseline and
produce more IL-1β and TNFα (181). However, how these aged microglia become
more pro-inflammatory remains unknown.
Many laboratories have investigated if microglia turnover in the brain throughout
the healthy lifespan of an individual, but it is largely believed that the microglia that
populate our CNS during embryonic development may reside there for the lifetime of
the mouse and even for several decades in humans (182, 183). Essentially, as we age
so do the microglia in our CNS. These microglia, however, alter their gene expression
with age to assume a more pro-inflammatory phenotype at baseline in a naïve CNS
(181). We hypothesized that microglia alter their epigenetic regulation to assume a
pro-inflammatory phenotype with age.
It has been shown that epigenetic regulation is essential to appropriate microglia
phenotype polarization. The histone demethylase, Jumonji Domain Containing 3
(Jmjd3, Kdm6b), is essential for anti-inflammatory phenotype polarization (163). Jmjd3
functions by removing histone H3 lysine 27 trimethylation (H3K27me3) marks to a
monomethylation mark (H3K27me1). This modification allows chromatin to go a from a
condensed structure with H3K27me3 marks to a more relaxed chromatin structure with
H3K27me1 (173). This change in chromatin structure allows for RNA Polymerase II
and transcription factors to bind to promoters and transcribe anti-inflammatory genes.
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The function of Jmjd3 is antagonized by Enhancer of Zeste Homologue 2 (Ezh2), which
is a histone lysine N-methyltransferase that functions to transfer methyl groups from
SAM molecules to H3K27me1 modifications to establish H3K27me3 marks (176). In
theory, this would reverse the effects of Jmjd3 to repress gene targets. Thus, we
hypothesize that Ezh2 and Jmjd3 lie in a functional antagonism and that Ezh2 is
essential for pro-inflammatory phenotype polarization.

Pro-inflammatory polarization of microglia results in increased deposition of
H3K27me3
We hypothesized that Ezh2 is essential to microglia pro-inflammatory polarization. We
first wanted to examine the possible role for Ezh2 in polarization of microglia. We
cultured BV-2 microglia cell line and then stimulated cells with LPS+IFNγ, IL-4, or PBS
vehicle control. We then collected cells 4 hours and 24 hours after stimulation for
analysis by Western blot. We found that following 24 hours of stimulation that there
was significant increase in H3K27me3 (Fig. 4.1). Additionally, we did find a significant
decrease in Ezh2 but not homologue Ezh1 at 24 hours of stimulation with LPS+IFNγ
(Fig. 4.1). We also further examined if LPS and/or IFNγ were independently
responsible for the increased H3K27me3 deposition that we observed following 24hr of
stimulation, however, we found H3K27me3 to be similarly increased at 24 hours of
stimulation with either LPS alone, IFNγ alone, or LPS+IFNγ combined (Fig. 4.2). Thus,
our results demonstrate that Ezh2 function may play a role in pro-inflammatory
polarization of microglia.
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Figure 4.1. Stimulation of BV-2 microglia with LPS+IFNγ results in increased
deposition of H3K27me3. BV-2 microglia cultures were stimulated with vehicle
control, 100ng/mL LPS + 10ng/mL IFNγ, or 20ng/mL IL-4 for 4 or 24 hours.
Representative Western blot of Jmjd3, Ezh2, Ezh1, H3K27me3, and β-actin loading
control immunoreactivity of 3 independent experiments.
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Figure 4.2. Stimulation of BV-2 microglia with LPS, IFNγ, or combined LPS+IFNγ
results in increased deposition of H3K27me3. BV-2 microglia cultures were
stimulated with vehicle control, 100ng/mL LPS + 10ng/mL IFNγ, or 20ng/mL IL-4 for 24
hours. Representative Western blot of Jmjd3, Ezh2, Ezh1, H3K27me3, and β-actin
loading control immunoreactivity of 3 independent experiments.
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Inhibition of Ezh2 results in abrogation of pro-inflammatory polarization
We wanted to investigate if inhibition of Ezh2 could block pro-inflammatory polarization
of microglia. Primary microglia were cultured and pre-treated with GSK343 or DMSO
vehicular control, and subsequently stimulated with LPS+IFNγ, IL-4, or 0.1% PBS
vehicular control. RT-PCR analysis demonstrated that inhibition of Ezh2 abrogated
LPS+IFNγ-induced up-regulation of pro-inflammatory genes Il1b, Tnfa, Il6, and Nos2
(Fig. 4.3). Additionally, inhibition of Ezh2 resulted in enhanced up-regulation of IL-4induced anti-inflammatory gene Arg1 (Fig. 4.4). These results suggest that Ezh2 is
essential for microglia pro-inflammatory phenotype polarization and may be involved in
repressing genetic transcription of anti-inflammatory genes.
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Figure 4.3. Pharmacological inhibition of Ezh2 results in decreased expression
of pro-inflammatory molecules. Primary microglia were cultured with 6uM GSK343
or DMSO vehicle control for 24 hours prior to stimulation with 100ng/mL LPS +
10ng/mL IFNγ, or 20ng/mL IL-4 for 24 hours in the presence of 6uM GSK343 or DMSO
vehicle control. Data are presented as the mean +/- SEM, n = 6/group, * p<0.05.
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Figure 4.4. Pharmacological inhibition of Ezh2 results in increased expression of
anti-inflammatory marker and Arg1. Primary microglia were cultured with 6uM
GSK343 or DMSO vehicle control for 24 hours prior to stimulation with 100ng/mL LPS
+ 10ng/mL IFNγ, or 20ng/mL IL-4 for 24 hours in the presence of 6uM GSK343 or
DMSO vehicle control. RT-PCR analysis using the ΔΔCt method was performed. Data
are presented as the mean +/- SEM, n = 6/group, * p<0.05, ** p<0.01.

77

Inhibition of Ezh2 results in decreased production of pro-inflammatory cytokines
To determine if Ezh2 is not only responsible for increased gene expression of proinflammatory genes, we cultured primary microglia as before and pre-treated with
GSK343 or DMSO vehicular control, and subsequently stimulated with LPS+IFNγ for
24 hours. We then collected media for multiplex cytokine analysis. We found that
pharmacological inhibition of Ezh2 results in decreased production of several proinflammatory cytokines, including IL-1β, IL-6, and TNFα (Fig. 4.5). These results
demonstrate that Ezh2 function is essential for pro-inflammatory phenotype polarization
of microglia.
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Figure 4.5. Pharmacological inhibition of Ezh2 results in decreased production
of pro-inflammatory cytokines. Primary microglia were cultured with 6uM GSK343 or
DMSO vehicle control for 24 hours prior to stimulation with 100ng/mL LPS + 10ng/mL
IFNγ for 24 hours in the presence of 6uM GSK343 or DMSO vehicle control. Multiplex
cytokine analysis was performed. Data are presented as the mean +/- SEM, Student’s
paired t-test, n = 6/group, * p<0.05, ** p<0.01, *** p<0.005.
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Conclusion
We found that polarization of microglia to a pro-inflammatory phenotype results
in increased deposition of H3K27me3 following 24 hours of stimulation with LPS+IFNγ,
a histone methylation mark established by Ezh2. Additionally, we found this mark to
increase following 24 hours of stimulation with LPS, IFNγ, or a combination of
LPS+IFNγ. As LPS and IFNγ are capable of independently polarizing microglia to a
pro-inflammatory phenotype (155, 156), this suggests that H3K27me3 is important to
the acquisition of a pro-inflammatory phenotype.
When we inhibited Ezh2 using the functional inhibitor GSK343, we found that in
the setting of a pro-inflammatory stimulus using LPS+IFNγ that the expression several
major pro-inflammatory molecules were decreased, notably Il1b, Il6, Tnfa, and Nos2.
This suggests that Ezh2 function is essential to the expression of pro-inflammatory
genes. Additionally, when we inhibited Ezh2 and stimulated cultures with IL-4 to induce
an anti-inflammatory phenotype, we found a significant increase in the expression of
anti-inflammatory marker Arg1. This suggests that Ezh2 has a role in the expression of
both pro- and anti-inflammatory gene sets, and functions to promote a pro-inflammatory
phenotype by simultaneously down-regulating anti-inflammatory genes.
When we examined the media of cultures following pro-inflammatory stimulation
with LPS+IFNγ with or without inhibition of Ezh2 with GSK343, we found that those
cultures with Ezh2 inhibition has significantly less pro-inflammatory cytokine production.
Collectively, our results demonstrate that Ezh2 is essential for pro-inflammatory
phenotype polarization of microglia.
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Chapter 5:
Heterochronic Parabiosis Rejuvenates the Epigenetic Status of the Aging Brain
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Rationale
Our results have shown that Ezh2 promotes pro-inflammatory polarization in microglia
(Chapter 4), and that the brain becomes epigenetically imbalanced with age to promote
a predominant pro-inflammatory phenotype (Chapter 3). Additionally, our work in vitro
demonstrates that plasma factors may promote a pro-inflammatory polarization of
microglia. Epigenetic modifications are, by definition, reversible and may be influenced
by response to the surrounding microenvironment. We questioned if the epigenetic
imbalance observed in the aging brain is 1) influenced by circulating peripheral factors
and 2) is potentially reversible. We chose to utilize a model of heterochronic parabiosis
to investigate the role of the circulating peripheral factors on the epigenetic landscape
of the aging brain.

Characterization of murine heterochronic parabiosis model
To determine if the epigenetic imbalance that occurs in the brains of mice with
age can be rejuvenated through manipulations in peripheral factors, we utilized a model
of heterochronic parabiosis in which young and aged mice are surgically joined and
come to share a common blood supply. This model has been well-established by other
labs and has been shown to have significant rejuvenation effects in the aged brain (83,
153).
Numerous studies and work from our own laboratory have demonstrated that the
intestinal microbiome can influence behavior tests (132, 184). In our model, we
perform all surgeries under strict sterile technique and intentionally do not use
antibiotics as part of our post-operative care in an effort to preserve the integrity of the
intestinal microbiome. This modification allows us to effectively study the mutual
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sharing of circulating cells, factors, metabolites from the intestinal microbiome, and the
interplay of all of these factors together with each other rather than individually
assessing the role of each potential factor (Fig. 5.1).

83

Figure 5.1. Model of heterochronic parabiosis. Young and aged animals are
surgically attached and allowed to share a common blood supply through
anastomoses. The model allows for the simultaneous transfer of cells, circulating
peripheral factors, and intestinal microbiome metabolites which provides substantial
power in conjunction with other animal models such as bone marrow chimerism,
plasma transfer, and microbiome transfer studies.
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We did not observe any mortality post-operatively due to infection, but rather all
mortality observed was due to parabiotic illness as determined by autopsy (Fig. 5.2).
Parabiotic illness is a condition which is believed to be caused by the development of
unequal anastomoses create an imbalance in the shared blood supply and one
parabiont accumulates blood while the other is depleted, and is essentially analogous
to twin-twin transfusion syndrome of monochorionic gestational twins(185).
Interestingly, the mortality from parabiotic illness was rare in young isochronic pairs but
equally observed between heterochronic and aged isochronics pairs (Fig. 5.2B, C).
Additionally, we found that nearly all mortality occurred by 4 weeks after surgery,
suggesting by this time post-operatively that anastomoses were well-established (Fig.
5.2B). We then allowed parabionts to live conjoined until 8 weeks post-operatively
before use in our studies. Weight loss of combined parabionts was highest in the aged
isochronic mice, but they maintained their post-operative weight loss by the time of
sacrifice (Fig. 5.2D). This is similar to our work with aged animals, in which aged
animals lose more weight post-operatively compared to young animals (125).
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Figure 5.2. Characterization of the heterochronic parabiosis model. (A)
Experimental timeline of the heterochronic parabiosis model. Mice were randomly
assigned to experimental groups and were pair-housed together for at least 1 week
prior to surgery. Parabionts were joined for 8 weeks prior to collection of samples for
further investigation. (B) Mortality of parabionts. We found heterochronic (HET) and
aged isochronic (A ISO) pairs to experience significant mortality compared to young
isochronic (Y ISO) pairs. (C) Parabiotic illness. Autopsy of deceased parabionts
demonstrates parabiotic illness, in which parabionts experience unequal blood
circulation. In the autopsy of the pair shown, the organs of one mouse were pale and
appear depleted of circulating blood (#1, top) while the other appears saturated with
blood (#2, bottom row), thus demonstrating an unequal share of the circulating blood
supply. (D) Weight loss of parabionts following surgery. Data are presented as a (B)
Kaplan-Meier curve, log-rank Mantel Cox analysis, ** p<0.01; (D) mean +/- SEM, logrank Mantel Cox analysis, ** p<0.01.
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Heterochronic parabiosis rejuvenates H3K27me3 in the aged brain
We investigated if heterochronic parabiosis can reverse the epigenetic
dysregulation that occurs in the brain with age (Fig. 5.3). Western blot analysis of
whole brain protein extracts revealed that the age-associated increase in H3K27me3
and decrease in H3K27me1 was maintained (Y ISO vs. A ISO, Fig. 5.3A, B). This
suggests that the parabiosis surgery itself does not disturb the epigenetic modifications
that occur with age in naïve animals (Fig. 3.3). Interestingly, we found that
heterochronic parabionts have levels of H3K27me3 that are reduced in the brains of A
HET mice relative to those of A ISO parabionts (Fig. 5.3A, B). However, the levels of
H3K27me3 were similar between Y ISO and Y HET animals, suggests that the
rejuvenation effect observed in A HET mice is not from a dilution effect of a detrimental
factor into Y HET animals. Together, this suggests there is a peripheral factor from the
young parabiont that is beneficial in reducing the levels of H3K27me3 in the aged brain.
Examination of H3K27me1 in parabionts demonstrated maintenance of the ageassociated decrease in our parabiosis surgical model (Y ISO vs. A ISO, Fig. 5A, C).
However, heterochronic parabiosis failed to increase levels of H3K27me1 in the A HET
brain (i.e. failed rejuvenation effect) and also failed to decrease levels in the Y HET
brain (i.e. failed accelerated aging effect) (A HET and Y HET, respectively, Fig. 5.3A,
C). This suggests that peripheral factors do not directly influence levels of H3K27me1.
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Figure 5.3. Heterochronic parabiosis rejuvenates age-associated increase of
brain H3K27me3. (A) Representative Western blot of whole brain samples of naïve
parabionts stained for H3K27me3, H3K27me1, and H3 total. (B) Quantification of
intensity of H3K27me3 relative to H3 total. (C) Quantification of intensity of H3K27me1
relative to H3 total. (D) Analysis of the ratio of H3K27me3 relative to H3K27me1. Data
are presented as the mean +/- SEM, two-way ANOVA with Tukey post-hoc test,
n=9/group, * p<0.05, **** p<0.001.
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Heterochronic parabiosis rejuvenates brain levels of IFNγ and GM-CSF
The primed phenotype of microglia is characterized by an increase in receptors
for signaling (e.g. MHC II, TLR4) and a decrease in molecules tampering the immune
response (e.g. CX3CR1, CD200R). However, while aged microglia are primed to
respond to pro-inflammatory signaling, others have found that there is no substantial
increase in basal production of inflammatory cytokines in naïve aged brains. Our data
presented here demonstrates that there is a significant increase in the basal levels of
inflammatory cytokine production in naïve brains with age when comparing brains of
mice of increasing age relative to 3-month-old mice (Fig. 3.4). Others in our lab have
used flow cytometry to demonstrate that aged microglia produce more TNFα and IL-1β
at baseline. It is important to note that these increases, while significant, are subtle and
thus detection of these differences likely depends on both the age of the young and
aged mice as well as the technique used.
Thus, given our results demonstrating an increase in basal production of
inflammatory cytokines with age, we first sought to characterize the levels of cytokines
in naïve parabionts brain and plasma using multiplex cytokine analysis. It is important
to note that at the time of sacrifice the Y ISO mice are similar to a 5- to 6-month-old
mouse and the A ISO are similar to a 20- to 22-month-old mouse. Thus, we anticipated
that any differences in baseline levels of cytokines in naïve parabionts would be subtle.
However, we found that there was a significant age-associated increase in IFNγ and
GM-CSF between Y ISO and A ISO groups (Fig. 5.4), which is consistent with our
findings in naïve mice. Importantly, this age-associated significant increase in IFNγ
and GM-CSF was not observed in A HET mice (Fig. 5.4). Thus, loss of this ageassociated increase in IFNγ and GM-CSF may suggest that the primed phenotype of
aged brain may be reversed in the brains of aged heterochronic parabionts.
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Figure 5.4. Heterochronic parabiosis reverses age-associated increase in brain
IFNγ and GM-CSF. Multiplex cytokine ELISA analysis results for IFNγ (A) and GMCSF (B) levels observed in the brains of naïve parabionts. Data are presented as the
mean +/- SEM, two-way ANOVA with Tukey post-hoc test, n=9-10/group, * p<0.05.
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Heterochronic parabiosis restores Aif1 and Itgam expression to younger levels
As we have shown, the expression of Aif1 and Itgam (which encode Iba1 and CD11b,
respectively) increase in the hippocampus of naïve mice with age (Fig. 3.5). Increased
expression of these molecules is associated with the primed phenotype of microglia.
We wanted to investigate if heterochronic parabiosis could reverse the age-associated
increased expression of these genes. In our model of heterochronic parabiosis, we
found that the aged hippocampus demonstrates an age-associated increase in both
Aif1 and Itgam (Y ISO vs. A ISO, Fig. 5.5). Interestingly, this up-regulation was not
observed in A HET mice (Y ISO vs. A HET, Fig. 5.5). This suggests that heterochronic
parabiosis restores the expression of Aif1 and Itgam to those of younger animals. This
also suggests that heterochronic parabiosis may reverse age-associated microglia
priming phenotype.
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Figure 5.5. Heterochronic parabiosis reverses age-associated increase in brain
Aif1 and Itgam. RT-PCR of hippocampus samples of naïve parabionts for Aif1 and
Itgam. Data are presented as the mean +/- SEM, two-way ANOVA with Tukey posthoc test, n=8/group, * p<0.05.
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Heterochronic parabiosis reverses the primed phenotype of aged brain
We observed rejuvenation of H3K27me3 in the A HET brain, which our in vitro
work suggests is involved in pro-inflammatory phenotype polarization. We also
observed rejuvenation of age-associated increase in brain levels of IFNγ and GM-CSF
in the A HET brain, both of which have been associated with the primed phenotype of
aged microglia. Together, these results suggest that the primed phenotype of aged
brain may be rejuvenated in the brains of A HET mice. To test this hypothesis, we
developed a novel model of neuroinflammation in heterochronic parabiosis. This model
utilizes the well-characterized neuroinflammatory model of peripheral stimulation by
intraperitoneal LPS injection. However, LPS cannot be accurately dosed by weight in
parabionts as the two animals are surgically attached to one another. Instead, we used
a consistent total amount of total LPS injected into all parabionts. If anything, aged
mice are heavier than young parabionts and in turn would receive a smaller dose of
LPS by weight. However, we hypothesize that aged animals will have a more
exaggerated neuroinflammatory response to LPS even in the setting of a smaller dose
by weight. Therefore, if anything, our model is conservative.
We injected parabionts with 100ug LPS intraperitoneally and collected samples
24 hours later. We found that the production of 14 of the 45 cytokines investigated
were elevated in brains of A ISO parabionts relative to A HET parabionts (Fig. 5.6). Of
particular interest, heterochronic parabiosis reduced the levels of IL-1β and IL-6, two
major cytokines involved in the pro-inflammatory response (Fig. 5.6). GM-CSF was
found to be significantly reduced in the brains of A HET mice following peripheral
stimulation with LPS (Fig. 5.6). CCL11, which has been found to be detrimental to
neurogeneration in the hippocampus with age, was also found to be reduced in brains
of A HET parabionts compared to A ISO surgical controls following LPS intraperitoneal
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stimulation (Fig. 5.6). This data suggests that heterochronic parabiosis rejuvenates the
age-associated primed phenotype of microglia.
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Figure 5.6. Heterochronic parabiosis reverses the age-associated primed
phenotype of the aging brain. Heterochronic and aged isochronic parabionts were
injected with 100ug LPS intraperitoneally and samples were collected 24 hours later.
Brain protein lysates were analyzed by multiplex cytokine ELISA analysis. The circles
represent those that were elevated in the A HET or A ISO parabionts, and the
overlapping region represents those analytes that were statistically similar between
parabionts. The 14 analytes that were found to be significantly elevated in the A ISO
parabionts relative to the A HET parabionts are shown. No analytes were found to be
significantly elevated in the A HET parabionts. Data are presented as the mean +/SEM, Student’s unpaired t-test, n=4-5/group, significance defined as p<0.05.
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Conclusions
Being the resident innate immune cell of the central nervous, microglia have the
potential to regulate homeostasis in the CNS as well as be some of the first cellular
responders to neurological injury. Microglia are plastic cells that reside in a resting,
surveillant phenotype and monitor the microenvironment for signals that may trigger an
immunological response. In the setting of an appropriate stimulus, microglia may
polarize their phenotype to a predominantly pro-inflammatory or anti-inflammatory
state. However, what is notable about microglia, is that they have a tendency to
transition from a resting, surveillant phenotype toward a pro-inflammatory phenotype
with age. However, the molecular mechanisms underlying this transition in baseline
phenotype with age have not been fully investigated.
This work first examines how the environment of the brain changes with age.
We first began by investigating how the inflammatory environment of the brain changes
with age. We developed a method to isolate protein samples in their native structure
for analysis by multiplex cytokine analysis, which requires their native structure to be
preserved for accurate and precise quantification. When we compare the levels of
analytes in the brains of mice across their healthy, naïve lifespan from 3-, 6-, 12-, 18-,
and 24-months of age, we find that many inflammatory molecules increase in the brain
over the life of mice (Fig. 3.4). These analytes increase compared to 3-month-old
naïve mice beginning at 6 months of age and progressively accumulate at 12-, 18-, and
24-months of age. These results suggest that the brain becomes progressively
inflammatory with age. This finding also corresponds with our finding that the brain
becomes epigenetically imbalanced with age. Our results demonstrate that there are
higher levels of H3K27me3 and lower levels of the antagonizing H3K27me1 histone
modification. This also corresponds with our finding that there is a decrease in Jmjd3
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levels in the brain with age, and a predominant increase in the ratio of Ezh2:Jmjd3 in
the brain with age as well. Together, these results suggest that the epigenetic
imbalance between Ezh2 and Jmjd3 in the brain with age is associated with the
accumulation of pro-inflammatory molecules in the brain.
However, epigenetic modifications are, by definition, reversible. Also, we found
that plasma from aged mice could induce up-regulation of pro-inflammatory cytokines
in primary microglia cultures (Fig. 3.7). We hypothesized that through heterochronic
parabiosis that the aged brain could be rejuvenated to a less pro-inflammatory status at
baseline. Our results demonstrate that exposure of the aged brain to young circulating
systemic factors rejuvenates the levels of H3K27me3 in the brain. Additionally, brain
levels of IFNγ and GM-CSF in A HET parabionts are also statistically similar to those of
Y ISO animals, signifying that exposure of the aged brain to the young periphery
reduces the levels of these two particular cytokines which are involved in ageassociated microglia phenotype priming. Finally, when we test this experimentally
through intraperitoneal injection with LPS into heterochronic and aged isochronic
parabionts, we find that there is a significant reduction of pro-inflammatory cytokines in
the brains of A HET mice relative to A ISO surgical controls. Collectively, this data
suggests that exposure of the aged brain to young circulating systemic factors
rejuvenates the primed phenotype of the aged brain. Ultimately, these findings suggest
that possible exposures in our environment may subtly
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Chapter 6:
Discussion and Future Directions
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The United States population is aging at an alarming rate. The Center for
Disease Control (CDC) estimates that the population of those age 65 and older in will
reach 30 million by 2020 and will double to 60 million by 2050 (186). This will place a
massive strain on the healthcare system, and interventions to assist in healthy aging
will become of greater importance in the very near future.
The brain withholds some of our body’s greatest functions and allows us to
function independently as individuals. It is the center of our thought processes and
cognition, and allows us to function as independent adults. However, aging exposes us
to the risk of age-associated neurological diseases which threaten our ability to think for
ourselves and may result in our dependence on others. Being able to maintain healthy
brain function will become essential to promote healthy aging in the United States and
around the world.
Our work investigates how the brain changes with age and possible
mechanisms that may partially responsible for brain aging. We are particularly focused
on the role of microglia in brain aging, which have been implicated in numerous
neuroinflammatory and neurodegenerative diseases, including Alzheimer’s and
Parkinson’s diseases. Being able to understand and potentially control microglia
phenotype may allow us to possibly prevent, delay, and/or treat these devastating
illnesses and allow people to age healthy and gracefully.
This work demonstrates how the brain changes epigenetically with age. The
epigenetic landscape is partially responsible for regulating gene expression, and
dysfunctional epigenetic regulation can lead to a dysfunctional and detrimental
phenotype. Our studies have identified that the ratio of global levels of Ezh2 and Jmjd3
and their respective histone modifications H3K27me3 and H3K27me1 become
imbalanced with age. Additionally, there is age-associated inflammation in the brain
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with age that progressively accumulates throughout the lifespan of healthy mice used in
our studies. Suspecting that microglia may be responsible for this dysfunctional
phenotype, we manipulated primary microglia cells in vitro using a pharmacological
inhibitor of Ezh2 in the setting of a pro-inflammatory stimulus. We found that inhibition
of Ezh2 diminishes the polarization of microglia to a pro-inflammatory phenotype and
enhances expression of anti-inflammatory genes. These findings suggest that Ezh2
lies at the balance of pro- and anti-inflammatory polarization, and promotes a proinflammatory phenotype by simultaneously up-regulating pro-inflammatory genes and
down-regulating anti-inflammatory genes.
Next, we aimed to identify if the circulating peripheral factors could influence the
epigenetic phenotype of the aging brain. To accomplish this, we used a surgical model
of heterochronic parabiosis in which a young and old mouse are surgically attached
and allow the two animals to share a common blood supply. The benefits of this model
are profound, and allow not only circulating peripheral factors to be examined, but also
the circulating peripheral cells, exposure to the intestinal microbiome of the other
parabiont, as well as the interplay of all of these factors. Using this model, we were
able to examine if the peripheral factors were responsible for brain aging or if
modifications associated with brain aging could be rejuvenated.
We found that exposure of the aged brain to a young periphery could reverse
the levels of H3K27me3 which are associated with a pro-inflammatory phenotype in
microglia. Additionally, aged animals exposed to a young parabiont (A HET) had
similar levels of IFNγ and GM-CSF in the naïve brain which are two molecules
implicated in microglia phenotype priming. We tested if the rejuvenation of H3K27me3,
IFNγ, and GM-CSF were functionally significant by exposing heterochronic and aged
isochronic parabionts to a neuroinflammatory stimulus via intraperitoneal LPS
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injections. We found that aged animals exposed to a young parabiont had significantly
reduced levels of numerous cytokines in the brain following a pro-inflammatory
stimulus. Together, these results demonstrate that circulating peripheral factors can
effectively rejuvenate the epigenetic landscape of the aged brain which results in
physiological improvement in the setting of a neuroinflammatory stimulus (Fig. 6.1).
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Figure 6.1. Summary of conclusions. This work demonstrates that through proinflammatory stimulation with LPS+IFNγ there is increased Ezh2 activity and transition
of microglia from a surveillant to a pro-inflammatory phenotype. Additionally, naïve
aging transitions the brain to a pro-inflammatory phenotype at baseline with associated
epigenetic imbalance between H3K27me3 and H3K27me1, with a predominance for
imbalance favoring H3K27me3. Heterochronic parabiosis can at least partially reverse
this effect of aging, thereby partially restoring the aged brain to a younger phenotype.
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Our studies are not without their limitations. Our studies have primarily focused
on the epigenetic changes and alterations in the environment of whole brain samples,
and have not specifically identified the age-associated epigenetic dysregulation of
microglia specifically. However, our in vitro studies begin to provide insight that proinflammatory polarization increases the deposition of H3K27me3 globally. Additionally,
we also found that inhibition of Ezh2 reduces the level of LPS+IFNγ-associated
deposition of H3K27me3 and up-regulation of pro-inflammatory genes (Figure 4.3).
To identify the role of H3K27me3 and its antagonizing activating histone
modification H3K27me1 in microglia specifically, flow assisted cytometric sorting
(FACS) analysis of these specific histone modifications in CD45int CD11b+ microglia is
limited. Histones interact to form an octameric nucleosome, which has been found to
be approximately 110 Å in diameter (187). Antibodies themselves are calculated to be
of similar size at approximately 100 Å (188). Thus, it is reasonably possible that the
physical size of antibodies (which likely have different binding affinities for their specific
targets) may perhaps interfere with each other from binding to nearby histones. In the
setting of flow cytometry multiple antibodies are simultaneously competing for their
targets. Thus, flow cytometry would likely give inaccurate results in an attempt to
quantify total levels of this histone proteins in microglia at the single cell level.
Our studies are also limited by currently available technology to identify if
specific epigenetic modifications at promoters of particular pro- and anti-inflammatory
genes are affected. Ideally, we would prefer to quantify the levels of H3K27me3,
H3K27me1, total histone H3, Ezh2, and Jmjd3 at the sites of promoters of proinflammatory and anti-inflammatory associated genes using chromatin
immunoprecipitation (ChIP). Given that pro- and anti-inflammatory phenotypes are
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defined by sets of genes as opposed to a single particular target, we would ideally
utilize ChIP-sequencing (ChIP-seq) technology. Unfortunately, these experiments are
limited by current available methods as the scientific community strives to reduce the
quantity of input required for ChIP-seq.
ChIP-seq technology is currently limited by the quantity of input in two ways.
First, one limitation is the quantity of the total input. If there is insufficient total input
DNA, detection of even abundant DNA-associated proteins will be difficult to detect. In
our lab, naïve young and aged animals have approximately 30-40,000 live CD45int
CD11b+ microglia cells per whole brain (125, 181, 189). Samples yielding these
quantities of microglia are fixed with paraformaldehyde which stabilizes antibody
binding while analyzing samples on the cytometer. However, to sort microglia for RNA
use (e.g. mRNA sequencing) or DNA uses (e.g. ChIP-seq), fresh cells must be used.
Microglia, in our experience, are fragile cells and do not tolerate in vitro or artificial
environments after extraction from the brain (18). Given these additional challenges,
we obtain approximately 10-15,000 live CD45int CD11b+ microglia cells per whole brain
(data not shown), which reduces the total available input for ChIP-seq. ChIPsequencing with low cellular input of approximately 10,000 cells per highly abundant
DNA-associated target proteins (e.g. total histone H3) is just beginning to become
possible and reliably reproducible with new techniques (190–192); however, performing
ChIP-sequencing for multiple targets from a single 10,000 cell sample is still not within
reach using the most up-to-date techniques at the writing of this thesis. As such these
experiments for our purposes are still not possible.
A second limitation of current ChIP-seq technology is the available DNAassociated quantity of the target molecule, such that if there is an insufficient level of
the DNA-associated protein within the sample, then there will be insufficient associated
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DNA to detect following immunoprecipitation. Ezh2 and Jmjd3 are likely transient DNAassociated protein molecules, making their detection in small sample sizes especially
challenging typically require the use of millions of cells for ChIP (163, 170). Due to
these cumulative limitations, we cannot directly address our hypothesis that aging
increases Ezh2 localization to specific DNA promoters of anti-inflammatory genes to
increase H3K27me3 locally resulting in their transcriptional down-regulation in vivo in
naïve animals or parabionts. Improvements in future techniques that allow for
reduction of sample input down to approximately 1,000 cells may allow for these ChIPsequencing experiments to be completed and provide insight into the underlying
molecular mechanisms of epigenetic regulation of aging.
Additionally, the model of heterochronic parabiosis is not without complications.
As discussed above in Chapter 5, heterochronic parabiosis is powerful in that it
examines the roles of circulating cells, soluble factors, and the simultaneous interplay
and interaction with each other. However, at the same time, this is a disadvantage
because it does not provide insight into a specific mechanism providing a significant
effect.
Also, as this is an in vivo surgical model, there are possible environmental
effects that may be influencing our results. One such possible effect may be the
relative physical activity of the animals within parabiont pairs. Young animals are
physically more active than their aged counterparts (193, 194); however, the relative
activity of young isochronic, heterochronic, and aged isochronic parabionts has not
been evaluated in this present study. This may be entirely plausible, as others have
shown in mice and in humans that those who exercise are generally healthier, with
improvements in mitochondrial function (195–197), neurogenesis (4, 193, 194, 198,
199), clearance of amyloid (80, 200), prevention of age-associated whole brain volume
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loss (201), and even reduction in microglia activation (88). While this is interesting to
speculate the role of exercise on brain aging and the possible role within the
heterochronic parabiosis model, evaluation of the role of exercise on the epigenetic
regulation of the aged brain is beyond the scope of this study but would be an exciting
extension of the work presented here.
Our studies presented did not specifically identify that the decrease in whole
brain H3K27me3 levels in aged heterochronic parabionts was due to a soluble plasma
factor. To address this question, this would require plasma transfer studies in which
the isolated plasma pooled from naïve young and naïve aged animals is transferred
into naïve aged and naïve young animals, respectively, as well as isochronic transfer
controls. These experiments require an extensive supply of animal resources and
require pooling plasma from approximately 500-2000 naïve animals of the same age
(83, 202). These experiments have been performed by others to demonstrate the
specific role of circulating soluble factors in reversing some aspects of brain aging (83,
202). However, perhaps more interestingly, transfer of umbilical plasma from human
samples has demonstrated a rejuvenating effect in aged mice in the setting of ischemic
stroke (203), olfactory function (204), and hippocampal function (205). We propose
that it may be a more cost-efficient and translational model to isolate plasma from
umbilical sources or healthy young donors as well as healthy aged donors to transfer
into young and aged mice. For the quantities of plasma required for these
experiments, human plasma is more readily available from healthy donors and would
also reduce the numbers of animals required for use in these studies. The use of
human plasma would also demonstrate a more translational approach to identify the
role of soluble factors on brain aging.
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Our studies identified that the circulating peripheral environment is at least
partially responsible for brain aging and may be a possible therapeutic route to promote
healthy brain aging. However, which particular factor(s) has not been identified in this
work. Ongoing studies are further examining plasma via mass spectroscopy, fecal
samples via 16S rRNA sequencing and metabolomic profiling, further examination of
the structural integrity of the intestine, as well as many others. We hope to be able to
identify select molecules that are responsible for brain aging that we may
pharmacologically target, as well as those beneficial molecules that are lost with brain
aging that we could potentially supplement.
However, these possible weaknesses of the heterochronic parabiosis model
could perceived as strengths. Aging is not a homogenous process. Most in vivo
studies use young animals, in part because they are less costly but also because there
is less variation in experimental values due to the homogeneity of the animals used to
represent the population. However, mice (as used in this study) and humans both die
at varying ages from biological processes that are heterogenous. Aging is complex,
and it is doubtful that one factor is responsible for the entirety of the aging process.
Similarly, it is equally doubtful that one factor is responsible for the maintenance of
youth. Thus, the model of heterochronic parabiosis may have weaknesses that may be
interpreted as strengths, or strengths that may be interpreted as weaknesses.
Ultimately, this is one experimental method that provides experimental evidence that
must be interpreted and discussed by the collective scientific community. We believe
the power of the model lies within the interplay of all factors, and the results could be
interpreted on a broader scale, such that being exposed to multiple youthful factors—
blood, social partner, microbiome, physical activity, etc.—may collectively be
rejuvenating to the aged brain.
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We do not intend to discover the fountain of youth. Rather we aim to identify
mechanisms that may promote healthy aging and possibly prevent onset of
neurological disease in high-risk individuals or those with an extensive family history.
By enabling the aging population to maintain their cognition and recovery from possible
neurological injuries, we may be able to enhance the quality of life and allow many to
continue to live independently. Life should be worth living, and maintaining healthy
neurological functions will allow us to continue to lead productive and enjoyable lives
until we must finally depart from this Earth.
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List of abbreviations
A HET
A ISO
AD
AIF-1
APP
ARG1
ATP
Aβ
CAA
CCI
CCL
CD
ChIP
CNS
CSF
CSF1R
CXCL
DIV
DNA
EED
Ezh1
Ezh2
FFAR2
FMO
GFP
GM-CSF
GPX1
H3K27me1
H3K27me2
H3K27me3
HDAC
HMGB1
Iba1
IFN
IL
iNOS
Int
IRF4
IRF5
Jmjd3
KDM
LPS
LTP
MAPK
MCP1
MHC
MIP

aged heterochronic
aged isochronic
Alzheimer’s disease
allograft inflammatory factor 1
amyloid precursor protein
Arginase-1
Adenosine triphosphate
amyloid β
Cerebral amyloid angiopathy
controlled cortical impact
chemokine (C-C motif) ligand
cluster of differentiation
chromatin immunoprecipitation
central nervous system
cerebrospinal fluid
colony stimulating factor 1 receptor
chemokine (C-X-C motif) ligand
day in vitro
deoxyribonucleic acid
embryonic ectoderm development
enhancer of zeste homologue 1
enhancer of zeste homologue 2
free fatty acid receptor 2
fluorescence minus one
green fluorescent protein
granulocyte macrophage colony stimulating factor
glutathione peroxidase 1
histone H3 lysine 27 monomethylation
histone H3 lysine 27 dimethylation
histone H3 lysine 27 trimethylation
histone deacetylase
high mobility group box 1 protein
ionized calcium binding adaptor molecule 1
interferon
interleukin
inducible nitric oxide synthase
intermediate
interferon regulatory factor 4
interferon regulatory factor 5
jumonji domain containing 3
lysine demethylase
lipopolysaccharide
long-term potentiation
mitogen-activated protein kinase
monocyte chemotactic protein 1
major histocompatibility complex
macrophage inflammatory protein
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MMP9
MRI
mTOR
NADPH
NFκβ
NgR1
NO
NOX
PBS
PKC
PRC1
PRC2
RAGE
RNA
ROS
ROS
SCFA
Seq
SOD1
SRA
Suz12
TBI
TGFβ
TLR
tMCAO
TNF
Y HET
Y ISO

matrix metalloproteinase 9
magnetic resonance imaging
mechanistic target of rapamycin
nicotinamide adenine dinucleotide phosphate
nuclear factor κ β
nogo receptor 1
nitric oxide
NADPH oxidase
phosphate-buffered saline
protein kinase C
polycomb repressive complex 1
polycomb repressive complex 2
receptor for advanced glycation end products
ribonucleic acid
reactive oxygen species
reactive oxygen species
short chain fatty acids
sequencing
superoxide dismutase 1
scavenger receptor A
suppressor of zeste 12
traumatic brain injury
transforming growth factor β
toll-like receptor
transient middle cerebral artery occlusion
tumor necrosis factor
young heterochronic
young isochronic
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